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Zusammenfassung 
p53 ist eines der wichtigsten Tumorsuppressor-Proteine. Die häufigsten biologischen 
Konsequenzen der p53-Aktivierung sind Zellzyklus-Arrest, Induktion von Apoptose 
und zelluläre Seneszenz. In der Zelle wird p53 hauptsächlich durch das Mdm2 
Protein, eine Ubiquitin Ligase die p53 dem Abbau in zellulären Proteasomen 
zuführt, kontrolliert. 
Obwohl p53 in etwa der Hälfte der menschlichen Tumore durch Mutation inaktiviert 
ist, ist es wegen seiner hohen anti-proliferativen Aktivität für die übrigen Fälle als 
mögliches Therapeutikum interessant. Um p53 für eine therapeutische Anwendung 
benutzen zu können, ist es notwendig zu wissen, wie p53 reguliert wird. 
In unserem Labor wurde Fam83F als neuer Regulator von p53 identifiziert. Für 
meine Doktorarbeit untersuchte ich den molekularen Mechanismus, mit dem 
Fam83F p53 reguliert. 
Ich konnte zeigen, dass Fam83F p53 in einer proteasom-abhängigen Weise durch 
Verringerung der p53-Ubiquitinierung stabilisiert. Fam83F interagiert mit dem C- 
Terminus von p53, der die Haupt-Ubiquitinierungsstellen enthält. Die durch Fam83F 
verursachte Zunahme der p53 Menge spiegelte sich auch in einer Zunahme der p53-
Aktivität wider. Als Reaktion auf DNA-Schäden wurde Fam83F induziert, was 
bereits darauf hindeutete, dass Fam83F zur Aktivierung von p53 nach DNA- 
Schäden beitragen könnte. Entsprechend war die Expression von p21 nach einer 
Schädigung der DNA in Zellen verringert, die mit Lentiviren infiziert worden waren 
welch für eine gegen Fam83F gerichtete shRNA kodierten. Die gleichen Lentiviren 
erhöhten auch die Zellproliferation. Fam83F ko-präzipitierte zwar auch mit 
mutiertem p53, führte aber nicht zu einer Mengenzunahme von mutiertem p53 
Protein.  
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ABSTRACT 
p53 is one of the most important tumor suppressor proteins. The most common 
biological consequences of p53 activation are cell cycle arrest, induction of 
apoptosis and cellular senescence. In the cell, p53 protein levels are kept under tight 
control by its negative regulator Mdm2, an ubiquitin ligase that targets p53 for 
degradation. 
Because of its anti-proliferative activity, p53 could potentially be used for cancer 
therapy. It is therefore important to determine how p53 is regulated. In our lab, we 
identified Fam83F as a novel regulator of p53 by performing a mammalian cell 
culture overexpression screen using a cDNA library from the teleost Medaka. For 
my PhD, I have investigated the molecular mechanism by which Fam83F regulates 
p53. 
My Data show that Fam83F stabilizes p53 in a proteasome-dependent manner, by 
reducing p53 ubiquitination. Fam83F interacts with the C-terminus of p53, which 
contains the main ubiquitination sites. The increase in p53 abundance caused by 
Fam83F was also reflected by an increase in p53 activity. Fam83F is induced in 
response to DNA damage, suggesting it may contribute to the activation of p53 
under these conditions. Indeed, knock-down of Fam83F in RKO cells reduced p21 
expression and increased the rate of cell proliferation. Fam83F also interacts with 
mutant p53 but does not increase the protein levels of mutant p53. 
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1. Introduction 
p53 was discovered in 1979 where it was found to co-precipitate with the large T- 
antigen of simian virus 40 (SV40) in extracts of SV40-transformed cells (Kress et 
al., 1979; Lane and Crawford, 1979; Linzer and Levine, 1979). At the same time, it 
was shown that cellular p53 levels were high in cells with functional T-antigen, but 
much lower in cells with mutated, non-functional T-antigen (Linzer et al., 1979). 
Soon thereafter, it was found that transformed cell lines expressed high levels of p53 
in comparison to non-transformed cells (DeLeo et al., 1979). A few years later, it 
was shown that co-transfection of a plasmid expressing p53 and of a plasmid 
encoding the oncogene ras led to cell transformation (Eliyahu et al., 1984; Parada et 
al., 1984). Even p53 on its own was found to immortalize early passage rat 
chondrocytes (Jenkins et al., 1984). Because of the tumor promoting activities p53 
was initially regarded as an oncogene (Jenkins et al., 1985) and it took several years 
to recognize that p53 is actually not an oncogene but a tumor suppressor protein. In 
these years several observations were made that finally led to the idea that p53 might 
be a tumor suppressor protein and not an oncogene. The first clue came from David 
Wolf and Varda Rotter, who found that p53 was inactivated by a retroviral insertion 
into the p53 gene in an Abelson-murine-leukemia-virus-transformed cell line (Wolf 
and Rotter, 1984; Wolf et al., 1984). Similar observations were reported in groups 
studying leukemia that were induced by the Friend erythroleukemia virus (Mowat et 
al., 1985; Ben David et al., 1988). It was furthermore reported that the p53 coding 
sequence was deleted in the human leukemia-derived cell line HL60 (Wolf and 
Rotter, 1985). These observations indicated that loosing p53 can promote cancer. 
However, at that time, these findings were considered as exceptional cases and their 
importance was not realized. In 1989, a new cDNA clone was investigated in the 
laboratory of Arnold Levine and with this clone it was not possible to reproduce the 
transforming effects that were observed with earlier clones of p53. The mystery was 
solved when the sequence of the novel cDNA clone of p53 and the sequence of the 
earlier clones were compared and it emerged that the sequences of the clones were 
not identical. This result suggested that at least some, if not all, of the clones carried 
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mutations in the p53 coding region (Finlay et al., 1989). This suggestion was 
approved when the sequence of wild-type p53 (wt p53) that was derived from 
normal, untransformed tissue, was established (Eliyahu et al., 1988; Finlay et al., 
1988). Subsequent experiments showed that p53 is indeed a tumor suppressor 
protein and that the cDNAs that were initially isolated were mutant forms of p53 
(Baker et al., 1989). 
1.1 p53: “Guardian of the genome” 
Genome integrity is based on equal segregation of faithfully repaired and replicated 
chromosomes to daughter cells during cell division. p53 controls these steps and thus 
maintains genomic integrity. Therefore, p53 is also called “guardian of the genome” 
(Lane, 1992). Upon DNA damage, p53 accumulates and induces cell cycle arrest at 
the restriction point at the end of the G1 phase (Kastan et al., 1991). This arrest of 
the cell cycle allows time to the cell to repair the DNA lesion prior to the next cell 
division. If the lesion cannot be repaired, p53 might also trigger cell suicide by 
apoptosis (Figure 1.1; Yonish-Rouach et al., 1991; Lane, 1992). 
 
 
 
 
 
 
 
 
 
Figure 1.1: p53 as a “guardian of the genome”. (a) p53 is not required during cell division.           
(b) In response to DNA damage, p53 is induced and initiates DNA repair or apoptosis. (c) Cells with 
mutant p53 replicate damaged DNA resulting in mutations and aneuploidy. (From: Lane, 1992). 
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How important the guardian of the genome function is displayed in several human 
and mouse cancer models that show that the increase in tetraploid and polyploidy 
tumor cells is correlated with loss of p53 function (Galipeau et al., 1995; Ramel et 
al., 1995). Moreover, p53-null mice frequently develop thymic lymphoma 
(Donehower et al., 1992). Sarcomas and lymphomas from p53+/- mice showed more 
chromosomal instability than tumors with two wild-type alleles (Venkatachalam et 
al., 1998). In addition, cells that possess wild-type p53 but are deficient in p53 
transcriptional targets such as p21 or gadd45 (growth arrest and DNA damage- 
inducible protein) also accumulate aberrant chromosomal numbers (Fukasawa et al., 
1997; Hollander et al., 1999; Mantel et al., 1999). Therefore, p53 is considered to be 
also “a guardian of ploidy” (Aylon and Oren, 2011). 
1.2  The structure of p53 
p53 is a nuclear phosphoprotein that is encoded by a twenty-kilobases-spanning gene 
located on chromosome 17. The gene contains 10 introns and 11 exons (Isobe et al., 
1986; Lamb and Crawford, 1986). The human p53 protein consists of 393 amino 
acids that are divided into several functional and structural domains (Figure 1.2). 
Residues 1-42 represent the N-terminus that contains the transactivation domain. 
This N-terminus is followed by a proline rich region that encompasses residues 61-
94. Residues 102-292 represent the central core domain that contains the DNA 
binding domain, and residues 301-393 represent the C-terminal region that holds the 
oligomerization domain (residues 324-355) and a basic carboxyterminal domain 
(residues 363-393). The C-terminal region also contains a nuclear export signal 
(NES) and a nuclear localization signal (NLS) that facilitate the shuttling of p53 
between the nucleus and the cytoplasm (Wang et al., 1992; Liang and Clarke, 1999; 
Stommel et al., 1999).  
The N-terminus of p53 is required for its transactivation activity (Lin et al., 1994). 
Mdm2 (murine double minute), a negative regulator of p53, associates with this N-
terminus of p53 (Oliner et al., 1993; Kussie et al., 1996). Mapping of the Mdm2-
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binding site on p53 showed the involvement of residues 18-26 of p53 in the 
interaction with Mdm2 (Böttger et al., 1997). Site-directed mutagenesis showed that 
residues Phe19, Trp23 and Leu26 are the most critical sites for the interaction 
(Böttger et al., 1997). Deletion of this Mdm2-binding site on p53 resulted in 
resistance to Mdm2-mediated degradation of p53 (Moll and Petrenko, 2003). The N-
terminus of p53 furthermore associates with p300/CBP (cAMP-response element 
binding protein (CREB)-Binding protein, Jenkins et al., 2009). p300/CBP, p53 and 
PML (promyelocytic leukemia protein) form a ternary complex in nuclear bodies 
that is required for p53 acetylation (Pearson et al., 2000). Phosphorylation of Ser15 
in the N-terminus of p53 increased the recruitment of p300/CBP (Lambert et al., 
1998) resulting in enhanced acetylation of lysine residues in the C-terminus of p53. 
This acetylation then leads to an increase in sequence-specific binding of p53 to 
DNA (Gu and Roeder, 1997). 
 
 
 
 
 
 
 
Figure 1.2: Structure of the p53 protein. The p53 protein contains 393 amino acids and is divided 
into several functional and structural domains. The N-terminus contains the transactivation domain 
(TA, residues 1-42) followed by a proline-rich region (PR; residues 61-94). The central core domain 
contains the DNA binding domain (residues 102-292). The C- terminal region contains the nuclear 
localization signal (NLS) followed by the oligomerization domain (Oligo, residues 324-355), the 
nuclear export signal (NES) and a basic carboxyterminal domain (residues 363-393). 
The N-terminus of p53 is followed by a proline-rich domain, a rigid linker that 
favors a polyproline II helix structure that keeps the transactivation domain of p53 
away from the DNA binding domain (Wells et al., 2008). The DNA-binding domain 
is required for sequence-specific DNA binding. The consensus sequence of of p53 
consists of two copies of the 10-bp motif: 5’PuPuPuC(A/T)-(T/A)GPyPyPy- 3’ 
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(Kern et al., 1991). Most p53 cancer mutations are located in the DNA binding 
domain (Joerger and Fersht, 2007). Particularly frequent are mutations found at 
residues Arg175, Gly245, Arg248, Arf249, Arg273, and Arg282 (Joerger et al., 
2006). The oncogenic mutations frequently decrease the stability of the 
thermodynamically unstable DNA-binding domain causing its rapid unfolding at 
body temperature (Friedler et al., 2003; Butler and Loh, 2006). 
The C-terminus of p53 plays a pivotal role in the sequence-specific DNA binding 
(Hupp et al., 1992). The C-terminus of p53 interferes with the binding of the DNA-
binding domain to the response elements and therefore functions as a negative 
regulatory domain (Anderson et al., 1997; Ahn and Prives, 2001; Vousden, 2002). 
Residues 80-93 of the proline-rich domain in the N-terminus of p53 furthermore 
associate with the C-terminus and thereby function as an additional negative 
regulatory domain of p53 (Muller-Tiemann et al., 1998). The C-terminus of p53 
furthermore contains the oligomerization domain, a domain that is responsible for 
the tetramerization of p53 (Jeffrey et al., 1995). In contrast to other transcription 
factors that oligomerize upon binding of ligands or upon association with DNA, p53 
is already present as a tetramer prior to its association with DNA (Friedman et al., 
1993). The oligomerization domain consists of a short β-strand and α-helix.  
Through the process of intermolecular α-helix packing and β-sheet formation 
assemble four monomers into a tightly packed p53 tetramer that binds to DNA very 
efficiently (Clore et al., 1994; Jeffrey et al., 1995). The tetramerization of p53 is 
furthermore essential for its C-terminal acetylation (Itahana et al., 2008). The basic 
carboxyterminal domain of p53 furthermore contains the main acetylation sites 
including Lys370, Lys372, Lys373, Lys381 and Lys382 (Gu and Roeder, 1997). 
These acetylation sites also serve as the main ubiquitination sites for p53 (Chan et 
al., 2006) and therefore also control the stability of the p53 protein (Lohrum et al., 
2001; Li et al., 2002). 
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1.3  The regulation of p53 abundance and activity 
The p53 protein is under tight regulation that is achieved by a network of positive 
and negative regulators. The levels of regulation are by (i) protein stability, (ii) 
protein activity and (iii) subcellular distribution (Jimenez et al., 1999; Meek, 1999; 
Prives and Hall, 1999; Ljungman, 2000). Posttranslational modifications (PTMs) 
play particular roles in the regulation of p53. Approximately fifty amino acids of p53 
are subjected to PTMs. These PTMs include ubiquitination, sumoylation, 
phosphorylation, acetylation, methylation, glycosylation, neddylation and poly- 
ribosylation (Boehme and Blattner, 2009). 
1.3.1 Regulation of p53 abundance 
P53 is present at very low amounts during normal cell proliferation. These low levels 
are due to rapid degradation after protein synthesis (Kubbutat and Vousden, 1998). 
Degradation of p53 occurs in 26S proteasomes and requires prior ubiquitination 
(Fang et al., 2000). Ubiquitination of proteins is performed by three classes of  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The ubiquitination cycle. Ubiquitination and degradation of proteins in 26S proteasomes 
occur through a sequential process involving three classes of enzymes: The E2 protein (ubiquitin 
activating enzyme) activates the ubiquitin molecule that is then conjugated to an E2 protein (ubiquitin 
conjugating enzyme). The E3 enzyme (ubiquitin ligase) recognizes a specific substrate protein and 
catalyzes the transfer of ubiquitin onto the target protein. 
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enzymes; an E1 enzyme (ubiquitin activating protein), an E2 enzyme (ubiquitin 
conjugating enzyme) and an E3 enzyme (ubiquitin ligase; Figure 1.3, Varshavsky, 
1997). The first step of ubiquitination is an ubiquitin-activating step. By utilizing 
ATP the E1 enzyme catalyzes the formation of ubiquitin adenylate. This 
intermediate then forms a high-energy thioester blond with a cysteine in the E1 
enzyme. Thereafter, the ubiquitin is transferred to a cysteine on an E2 enzyme. In the 
final step the E3 enzyme mediates the formation of an isopeptide bond between the 
C-terminus of ubiquitin and a ε-amino group of a lysine residue in the target protein 
(Glickman and Ciechanover, 2002). The E3 enzyme plays the main role in the 
recognition of substrates (Hershko and Ciechanover, 1992).  
Amongst the ten E3 proteins that are reported to control p53 abundance is the RING 
domain ubiquitin ligase Mdm2 of highest importance for p53 (Boehme and Blattner, 
2009). Mdm2 is, for instance, essential for preventing p53 activation during 
embryonic development. Mice with a genetic deletion of both Mdm2 alleles die 
during embryogenesis, but they survive when they also lack the p53 gene (Jones et 
al., 1995; Montes de Oca-Luna et al., 1995). The mdm2 gene (Figure 1.4) was 
initially discovered on a double minute chromosome of spontaneously transformed 
mouse 3T3 fibroblasts (Cahilly-Snyder et al., 1987). 
 
 
 
 
 
Figure 1.4: Structure of the Mdm2 protein. The drawing shows the full-length Mdm2 protein. 
Known motifs are indicated. The p53 interaction domain is located in the amino terminal domain. 
NLS: nuclear localization signal; NES: nuclear export signal; zn-finger: zinc-finger domain; NoLS: 
nuclear localization signal; RING: (really interesting new gene) finger domain has an ubiquitin ligase 
domain (modified from: Iwakuma and Lozano, 2003). 
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Soon after its identification, Mdm2 was found to interact with p53 (Momand et al., 
1992) and a couple of years later, it was found that Mdm2 possesses ubiquitin ligase 
towards p53 (Figure 1.5, Honda and Yasuda, 2000). Importantly, Mdm2 itself is a 
target gene of p53 (Barak et al., 1993; Juven et al., 1993). Thus, p53 and Mdm2 are 
connected to each other through a negative feedback loop that ensures that cellular 
p53 levels are kept low in the absence of stress (Picksley and Lane, 1993). 
 
 
 
 
 
 
 
 
 
Figure 1.5: Control of p53 stability by Mdm2. During normal cellular conditions the activity of p53 
is maintained at low levels by its negative regulator Mdm2. Mdm2 binds to p53 and mediates its 
ubiquitination which allows its recognition by 26S proteasomes where p53 is digested into 
oligopeptides. 
Crystallographic analysis of the p53-Mdm2 interaction revealed the biochemical 
basis of the Mdm2-mediated inhibition of p53. Mdm2 can antagonize p53 by 
concealing its transactivation domain. It achieves this by binding to an N-terminal 
region of p53 thereby blocking its ability to associate with the transcriptional 
machinery (Oliner et al., 1993; Chi et al., 2005). Mdm2 shuttles between the nucleus 
and the cytoplasm (Roth et al., 1998). This shuttling activity required the nuclear 
export sequence of Mdm2 (Iwakuma and Lozano, 2003). Mutation of the nuclear 
export sequence of Mdm2 abolishes Mdm2 nuclear export and also p53 degradation, 
implying that Mdm2 binds p53 in the nucleus and transports it into the cytoplasm 
where it is degraded (Tao and Levine, 1999).  
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Mdm2 mediates monoubiquitination and polyubiquitination of p53 (Li et al., 2003). 
The level of Mdm2 determines which activity will be performed. Low levels of 
Mdm2 activity in unstressed cells induce nuclear export while high levels of Mdm2 
induce p53 polyubiquitination and degradation in the nucleus in order to suppress 
p53 function (Brooks and Gu, 2006).  
p300 which is considered to be an E4 ligase for p53 is required for 
polyubiquitination of p53. It associates with Mdm2 and finalizes the process of 
polyubiquitination (Grossman et al., 2003). PirH2, another E3 ubiquitin ligase, also 
antagonizes p53 function. It interacts with p53 and promotes p53 ubiquitination 
independent of Mdm2 (Leng et al., 2003). Deubiquitination of p53, on the other 
hand, is achieved by HAUSP (herpesvirus-associated ubiquitin-specific protease (Li 
et al., 2002). 
1.3.2 Activation of p53 
p53 is activated and stabilized in response to cellular stress. DNA damaging agents 
such as ionizing radiation, ultraviolet light or some anticancer drugs lead to rapid 
accumulation of the p53 protein (Giaccia and Kastan, 1998). Disruption of the 
interaction of p53 with its negative regulator Mdm2 is the first step in the p53 
activation cascade. Ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia 
and Rad3-related (ATR) trigger a variety of post-translational modifications of p53 
that promote its stabilization and activation. Phosphorylation of p53 at ser15 and 
ser20 after DNA damage, for instance, has been shown to inhibit the interaction 
between p53 and Mdm2 leading to p53 stabilization (Shieh et al., 1997; Chehab et 
al., 2000; Shieh et al., 2000; Schon et al., 2002). ATM furthermore phosphorylates 
the checkpoint kinase-2 (Chk2, Matsuoka et al., 2000) that is followed by 
phosphorylation of p53 at ser20 (Chehab et al., 1999; Hirao et al., 2000). Protein 
kinases like ATM and ATR furthermore activate p53 by mediating the degradation 
of Mdm2 (Stommel and Wahl, 2004).  
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Phosphorylation is indeed the most studied posttranslational modification of p53. 
Ser33, one of p53 phosphorylation sites, was found to be constitutively 
phosphorylated by glycogen synthase kinase-3 beta (GSK-3β) and by the cdk- 
activating kinase (CAK) complex (Ko et al., 1997; Turenne and Price, 2001). It was 
also reported that p53 is phosphorylated at thr55 by the TATA-box-binding protein-
associated factor 1 (TAF1). Phosphorylation of this site enhances the association of 
p53 with CRM1 (chromosomal region maintenance-1), a protein that triggers 
cytoplasmic translocation of p53 (Gatti et al., 2000; Li et al., 2004; Cai and Liu, 
2008). Phosphorylation of Mdm2 also has an impact on p53 activity. 
Phosphorylation of Mdm2 at ser395, for instance, reduces the translocation of p53 
from the nucleus to the cytoplasm, resulting in increased p53 stability (Gajjar et al., 
2012). 
Acetylation is, furthermore, a critical post-translational modification for p53 activity 
that increases the sequence-specific binding of p53 to DNA (Sykes et al., 2006). The 
three acetyltransferases p300/CBP (cAMP-response element binding protein 
(CREB)-Binding protein), PCAF (p300/CBP-associated factor) and hMOF/TIP60 
(human males absent on the first/Tat-interactive protein of 60 kDa) play a pivotal 
role in p53 activation (Scolnick et al., 1997; Lin et al., 1999; Legube et al., 2004). To 
induce transcription of its target genes, p53 needs to interact with co-factors of 
transcription. p300/CBP, p53 and PML form a complex in nuclear bodies that is 
required for p53 acetylation by p300/CBP (Pearson et al., 2000). This association of 
p300/CBP with p53 is enhanced by N-terminal phosphorylations (Polley et al., 2008; 
Jenkins et al., 2009). Lys164, lys305, lys370, lys372, lys373, lys381, lys382, and 
lys386 can all be acetylated by p300/CBP (Gu et al., 1997). This acetylation of p53 
by p300/CBP induces its pro-apoptotic activity (Knights et al., 2006). In response to 
DNA damage, PTEN (phosphatase and tensin homolog) forms a complex with 
p300/CBP and this enhances p300/CBP activity and acetylation of p53 (Li et al., 
2006). p300/CBP furthermore cooperates with Mdm2 and function as an E4 
ubiquitin ligase to promote p53 polyubiquitination (Shi et al., 2009, Grossman et al., 
2003). In contrast to p300/CBP, PCAF and hMOF/TIP60 do not need special 
conditions to function. According to the regulation of p53 by acetylation, p53 can 
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also be regulated by histone deacetylases (HDACs). Protein complexes containing 
HDAC1 or NAD-dependent protein deacetylase sirtuin-1 (SIRT1) strongly repress 
p53-dependent transcription and reverse p53 dependent growth arrest and apoptosis 
in response to DNA damage (Juan et al., 2000; Luo et al., 2000; Luo et al., 2001; 
Vaziri et al., 2001). Mdm2 can recruit HDAC1 to p53 and facilitate HDAC1-
mediated deacetylation of p53 (Ito et al., 2002).  
p53 is also modified by methylation, sumoylation and neddylation. p53 is, for 
instance, methylated at lys370 by Smyd2 (SET and MYND domain-containing 
protein 2), at lys372 by SET 7/9, and at lys382 by SET8 (Chuikov et al., 2004; 
Huang et al., 2006; Ivanov et al., 2007; Shi et al., 2007; Kurash et al., 2008). 
Methylation of lys370 and lys382 inhibits DNA binding and transcriptional activity 
of p53 and methylation of lys382 impairs acetylation of this site (Huang et al., 2006; 
Shi et al., 2007).  
The activity of p53 depends on its subcellular localization and both, nuclear export 
and import of p53 are tightly regulated (O’Brate and Giannakakou, 2003). The 
shuttling of p53 between the nucleus and cytoplasm is regulated by the nuclear 
localization signal (NLS) and the nuclear export signal (NES, Liang and Clarke, 
1999; Stommel et al., 1999; Zhang and Xiong, 2001). p53 is synthesized in the 
cytoplasm and needs to be transported into the nucleus to exert its transcriptional 
activity after cellular stress. This accumulation in the nucleus is important for its 
tumor suppressive activity. Cytoplasmic sequestration of p53 was observed in 
certain tumors like neuroblastomas and in breast and colon cancer (Moll et al., 1992; 
Bosari et al., 1995; Moll et al., 1995; Ostermeyer et al., 1996). After cellular stress, 
like DNA damage, p53 gets imported into the nucleus through its NLS, undergoes 
tetramerization and binds to and activates its target genes (Jimenez et al., 1999). The 
p53 tetramer masks its NES and thereby blocks nuclear export (Stommel et al., 
1999). Several proteins can influence p53 subcellular localization. One of the most 
important of these proteins is Mdm2. Mdm2 also contributes to the cytoplasmic 
sequestration of p53 in some tumors (Lu et al., 2000).  
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Beside DNA damage, p53 is also induced and activated in response to activated 
oncogenes. p19ARF, the alternate reading frame product of the p16/INK4A locus is 
a major mediator of this induction. p19ARF interacts with Mdm2 upon oncogenic 
stress and sequesters it in the nucleolus and thus away from p53 (Weber et al., 1999; 
Sherr, 2006). Since loss of p19ARF does not prevent the activation of p53 in 
response to DNA damage, it is most likely that oncogenic stress and DNA damage 
use different and independent pathways for activating p53 (Stott et al., 1998; Kamijo 
et al., 1999). 
1.4 The physiologic functions of p53 
The p53 tumor suppressor protein is involved in many cellular processes including 
cell differentiation, cell cycle regulation, apoptosis, senescence, DNA repair and 
metabolism (Shaw, 1996; Fridman and Lowe, 2003; Meek, 2004; Teodoro et al., 
2007; Vousden and Ryan, 2009; Rufini et al., 2013). These activities are mediated 
by different activities of p53 such as transcriptional activation, transrepression and 
exonuclease activity. A large set of p53 target genes is involved in these cellular 
processes (Figure 1.6, Amundson et al., 1998; Giacca and Kastan, 1998). The high 
p53 levels induced by various stress types prevent inappropriate proliferation of cells 
carrying damaged DNA. Transcription-dependent and transcription- independent 
mechanisms in the nucleus and mitochondria contribute to the prevention of cell 
proliferation in response to stress (Vousden, 2002; Mihara et al., 2003). 
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Figure 1.6: Activation of p53 and induction of p53 target genes. In response to various stress 
signals, such as oncogenic stress, hypoxia, ribosomal stress, DNA damage, telomere erosion and 
others, p53 becomes activated and induces the expression of an array of target genes including p21, 
PUMA, DRAM, DDB2 and AMPK. The activation of p53 target genes leads to biological responses 
such as cell cycle arrest, DNA repair, apoptosis, senescence, autophagy or alteration of cell 
metabolism (From: Hao and Cho, 2014). 
1.4.1 Transcription-dependent activities of p53 
1.4.1.1  p53-dependent induction of cell cycle arrest 
The cell cycle is regulated at two major check points: a checkpoint at the G1/S 
boundary, after which cells can proceed into S-phase and become committed to 
DNA synthesis, and a checkpoint at the G2/M boundary, after which cells progress 
to mitosis (Barnum and O’Connell, 2014). The critical signals for both transitions 
result from the cell cycle-specific phosphorylation of several substrates including 
pRb in the case of the G1/S boundary and tyrosine kinases and histone H1 in the 
case of the G2/M transition (Nigg, 1993a). These phosphorylations are mediated by 
p34cdc2 protein kinases (Nigg, 1993b). These cell cycle regulators were initially 
identified as the products of the two cell division cycle (cdc) genes cdc2 from the 
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fission yeast Saccharomyces pompe and cdc28 from the budding yeast 
Saccharomyces cerevisiae (Mendenhall and Hodge, 1998). The activity of these 
kinases requires their association with cyclins that act as essential activation subunits 
(Reed et al., 1992).  
The cyclin family is divided into three classes, based on their physiological function. 
D-type cyclins are required during the G1 phase of the cell cycle. A-type cyclins 
guide the progression through the S-phase and B-type cyclins are active during 
mitosis (Malumbres, 2014). In contrast to yeast cells, where a single p34cdc2/cdc28 
kinase controls both the G1/S and the G2/M transition, vertebrates possess a multi-
gene family of homologous kinases that control the cell cycle (Meyerson et al., 
1992). Cell cycle progression is controlled by the sequential formation, activation 
and inactivation of cyclin-cdk complexes (Vermeulen et al., 2003). The discovery of 
a family of cdk inhibitors suggested a mechanism by which the activity of cyclin-cdk 
complexes can be controlled. Such inhibitors bind to cyclin- cdk complexes and 
inhibit their kinase activity (Hunter, 1993). The first of the cdk-inhibitors that has 
been discovered and characterized was p21/WAF1/CIP1/Sdit (wild-type p53 
activated fragement-1/cyclin-dependent kinase (cdk)-interacting protein-1), a p53 
regulated gene (Harper et al., 1993). p21-deficient cells show an aberrant G1 arrest 
after exposure to radiation (Deng et al., 1995). p21 also contributes to the G2 arrest 
by inhibiting the cyclinB1/cdc2 activity that is crucial for cells to enter mitosis (Dash 
et al., 2005). p21 is up-regulated by p53 in response to DNA damage (DiLeonardo et 
al., 1994) and is considered to play an important role in the p53-mediated growth 
arrest (El-Deiry et al., 1994). Loss of the G1/S checkpoint or impaired G2 arrest as a 
result of p53 inactivation can give rise to aneuploid or polyploid cell indicating that 
the ability of p53 to halt cells at different checkpoints of the cell cycle is vital for its 
tumor suppressive activity (Bunz et al., 1998; Meek, 2000). p21 is furthermore 
necessary for p53-mediated repression of genes including cdc2, cdc25C and tert 
(telomerase reverse transcriptase, Löhr et al., 2003; Shats et al., 2004). Regulation of 
p21 by p53 apparently occurs at the level of transcription as the ability of p53 to 
induce growth arrest requires its transactivation domain (Pietenpol et al., 1994). Loss 
of p53 results in a dramatic reduction in p21 levels (El-Deiry et al., 1994). 
Introduction  
23 
 
1.4.1.2  p53-dependent induction of apoptosis  
Apoptosis, also called “programmed cell death” is a special form of cell death (Kerr, 
2002). Several target genes of p53 including bcl-2 (B-cell lymphoma 2), bax (bcl-2-
associated X protein), puma (p53-upregulated modulator of apoptosis), pmaip1 
(phorbol-12-myristate-13-acetate-induced protein 1) also known as noxa and bid 
(BH3-interacting-domain) contribute to the induction of p53-dependent apoptosis 
(Miyashita et al., 1994; Oda et al., 2000; Nakano and Vousden, 2001; Say et al., 
2002). The bax gene promoter responds to p53 activation because of the presence of 
a p53 binding site (Miyashita et al., 1994). Thereafter accumulates the pro-apoptotic 
Bax protein in mitochondria. The activated Bax protein assembles a protein complex 
that is called the permeability transition pore (PTP). This creates a channel through 
both membranes of the mitochondria resulting in swelling of the mitochondrial 
matrix and eventually in rupture of the mitochondria outer membrane (Schwarz et 
al., 2007). Ionizing radiation also induces noxa in a p53-dependent manner. The 
Noxa protein contains a BH3 (Bcl-2-homology domain 3) motif that is found widely 
on Bcl-2 family members. Noxa localizes to mitochondria and interacts with anti-
apoptotic Bcl-2 family members like Bcl-XL (B-cell lymphoma- extra-large) and 
Mcl-1 (myeloid leukemia cell differentiation protein) through its BH3 domain. Puma 
also encodes a BH3-containing protein that localizes to mitochondria. With its BH3 
domain Puma interacts with Bcl-2 and Bcl-XL and induces apoptosis by inducing 
Cytochrome C release and activation of Caspase 3 and 9 (Benchimol, 2001). 
1.4.1.3  p53-dependent regulation of cellular metabolism 
Fatty acids are important metabolic intermediates that play a pivotal role in lipid 
synthesis. Fatty acids are, moreover, used in the mitochondria to generate ATP 
through beta oxidation. In response to genotoxic stress and glucose deprivation, p53 
modulates the oxidation of fatty acids by increasing guanidinacetate N- 
methyltransferase levels. Guanidinacetate N-methyltransferase in turn converts 
guanidinacetate to creatine and this enhances the energy metabolism (Zhu and 
Prives, 2009). 
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1.4.2 Transcription-independent activities of p53 
Beside transcription-dependent cellular responses, p53 can also induce apoptosis in 
the cytoplasm (Arima et al., 2005; Speidel et al., 2006). Particularly after DNA 
damage, p53 shuttles to mitochondria where it associates with members of the Bcl-2 
family (Mihara et al., 2003; Chipuk et al., 2004). This association of p53 with 
members of the Bcl-2 family leads to the permeabilization of the outer membrane of 
mitochondria and to the release of Cytochrome C (Wolff et al., 2008). 
1.5   Mutant p53 
p53 is mutated in about 50% of all human cancers (Rivlin et al., 2011). In contrast to 
other tumor suppressor genes that are usually inactivated in cancer, the majority of 
cancer-associated mutations of the p53 gene are missense mutations (Weinberg, 
1991; Harris and Hollstein, 1993). Most of these missense mutations are clustered 
within the central DNA binding domain (Cho et al., 1994). Wintin the DNA binding 
domain there are several mutation hot spots including R175, G245, R248, R249, 
R273 and R282 (Olivier et al., 2002).  
In 1993, it was observed that mutant p53 shows a gain of function when mutant p53 
was transfected into p53 null cells (Dittmer et al., 1993). This result that mutant p53 
is not silent but has frequently gained novel, tumorigenic activities was further 
supported by the observation that patients carrying a p53 missense mutation in the 
germline have a significantly earlier onset of cancer than patients with mutations in 
the p53 gene that result in loss of p53 protein expression (Bougeard et al., 2008; 
Zerdoumi et al., 2013). Likewise, mice that expressed mutant p53 showed a tumor 
profile that was more metastatic and aggressive than mice that expressed wild-type 
p53 or mice with two deleted alleles of p53 (Lang et al., 2004; Olive et al., 2004; 
Doyle et al., 2010; Morton et al., 2010). Xenografts harboring mutant p53, 
furthermore, also showed enhanced tumor invasion (Adorno et al., 2009; Muller et 
al., 2009).  
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How mutant p53 exert its pro-oncogenic effect is not fully understood. The first 
model that has been proposed says that mutant p53 retains a residual transactivation 
activity and has an impact on chromatin by inducing MLL1/2 (mixed lineage 
leukemia protein 1/2) and MOZ (monocytic leukemia zinc finger protein (Zhu et al., 
2015). The second model that has been proposed is that certain unstructured mutants 
of p53 sequester other proteins that enable mutant p53 to bind p63 or p73 resulting 
in changes in the transcriptional profiles that e.g. alter receptor tyrosine kinase 
signaling resulting in invasion and metastasis (Muller et al., 2009; Weismueller et 
al., 2014). The third model proposes that mutant p53 can cooperate with the 
SWI/SNF complex (Switch/Sucrose non-fermentable) to upregulated VEGFR2 
(vascular endothelial growth factor) that is considered as an important regulator of 
angiogenesis (Pfister et al., 2015). 
1.6  Family with sequence similarity 83 
The Fam83 (Family with sequence similarity 83) family is a family of proteins that 
includes eight members (Fam83A-H). The Fam83 family is characterized by the 
presence of a highly conserved domain, the DUF 1669 (domain of unknown 
function) domain (Cipriano et al., 2014). Each member of the Fam83 family is 
located at a distinct genomic site. fam83 genes are only found in jawed vertebrates. 
There are no homologues or orthologues of fam83 in primitive organisms such as 
Saccharomyces cerevisiae or Drosophila melanogaster (Bartel et al., 2016). Several 
members of the Fam83 protein family have oncogenic properties (Cipriano et al., 
2012; Grant, 2012; Cipriano et al., 2013; Cipriano et al., 2014; Bartel et al., 2016; 
Snijders et al., 2017). Fam83A, for example, is interacting with c-Raf and PI3Kp85 
(Phosphoinosite-3-kinase) and its overexpression in cancer is correlated with poor 
prognosis of breast cancer patients (Lee et al., 2012; Bartel and Jackson, 2017). By 
activating TGF-β and Wnt signaling, Fam83A plays a vital role in pancreatic cancer 
(Chen et al., 2017). Fam83B, Fam83C and Fam83E were identified as potential 
oncogenes that transform immortalized mammary epithelial cells (Snijders et al., 
2017). Fam83B has also been shown to activate MAPK (mitogen-activated protein 
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kinase) signaling (Cipriano et al., 2014). Many human tumors show high levels of 
Fam83B mRNA. Ablation of Fam83B inhibited proliferation, anchorage-
independent growth and tumorigenicity of breast cancer cells (Cipriano et al., 2012). 
Fam83D (also called C20orf129 or CHICA) localizes to spindle microtubules and 
plays a role in the distribution of sister chromatids (Sauer et al., 2005). Fam83D-
deficient cells show malfunctioning of the spindle resulting in enhanced 
chromosome missegregation and aneuploidy (Santamaria et al., 2008). Fam83D is 
amplified and overexpressed in many human cancers (Liao et al., 2015; Walian et 
al., 2016). Forced expression of Fam83D in non-malignant cells reduces the 
expression of the fbxw7 (F-box and WD repeat domain-containing protein 7) tumor 
suppressor gene and promotes proliferation and invasion (Wang et al., 2013). 
Fam83H is a keratin-associated protein that regulates the organization of the 
cytoskeleton. Cancer cells with overexpression of Fam83H loose cell polarity and 
keratin filaments and show increased invasion and metastasis of colorectal cancer 
(Kuga et al., 2013). 
 
 
 
 
Figure 1.7: The Fam83 protein family. Members of the Fam83 protein family are characterized by 
the highly conserved N-terminal domain of unknown function 1669 (DUF1669, from: Bartel et al., 
2016). 
Analysis of the human proteome indicates that members of the Fam83 protein family 
are expressed in several tissues, yet at low levels, particularly in comparison with 
other proto-oncogenes such as the epidermal growth factor receptor (EGFR) or K-
Ras (Kirsten rat sarcoma; Bartel et al., 2016). 
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Figure 1.8: Expression of Fam83 family members. The table shows expression of the Fam83 
family members Fam83A-H and of the epidermal growth factor receptor (EGFR), K-Ras (Kirsten rat 
sarcoma) and beta actin. The tissue types include the blood and immune system, the nervous system, 
the muscoskeletal system, the internal and secretory system and the reproductive system (from: Bartel 
et al., 2016). 
1.6.1  Family with sequence similarity 83 member F 
The fam83F gene is found on chromosome 22q13.1. Forced expression of fam83F  
in H1299 cells was observed to increase p53 abundance (Zhang et al., 2015). More 
recently, it was found that fam83F expression was increased in esophageal  
squamous cell carcinoma. Introduction of miR-143 into esophageal cancer cells 
down-regulated fam83F expression which resulted in inhibition of cell proliferation, 
migration and invasion (Mao et al., 2016). miR-143 is downregulated and functions 
as a tumor suppressor in several tumors including bladder cancer, cervical cancer 
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and prostate cancer (Noguchi et al., 2011; Chen et al., 2014; Zhou et al., 2015). The 
3’UTR of Fam83F mRNA is a direct target of miR-143. Overexpressing or silencing 
miR-143 in esophageal squamous cell carcinoma cells showed that miR-143 
regulates Fam83F expression by decreasing the stability of its mRNA (Mao et al., 
2016). Fam83F is upregulated in head-and neck cancer, breast and lung cancer and 
increased expression of Fam83F is associated with poor patient survival (Snijders et 
al., 2016). 
1.7 Aim of the project 
p53 is regulated by a complex network of positive and negative regulators and the 
mechanism by which p53 is controlled in different cell types and growth conditions 
is not fully understood. Screening a cDNA library from the teleost Medaka for novel 
regulators of p53 showed for the first time that Fam83F is a novel regulator of p53 
(Zhang et al., 2015).  
The aim of this study is to investigate the molecular mechanism by which Fam83F 
regulates p53 abundance and to explore its function in the context of p53. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and consumables 
Chemicals Source 
Acetic Acid Merck, Darmstadt 
Acetone Roth, Karlsruhe 
Adenosine 5′-triphosphate (ATP) disodium 
Salt 
Sigma-Aldrich, Taufkirchen 
Agar Nordwald, Erlangen 
Agarose Peqlab, Erlangen 
Amersham ECL Hyperfilm GE Healthcare, Freiburg 
Amersham
TM 
ECL
TM 
Prime Western Blotting 
Detection Reagent (Highly chemiluminescent 
detection reagent)   
GE Healthcare Life 
Sciences,Freiburg, Germany  
Ammonium persulfate (APS) Sigma-Aldrich, Taufkirchen 
Ampicillin, sodium salt Roth, Karlsruhe 
Aqua-Poly/Mount 
Polysciences Europe GmbH, 
Germany 
β-mercaptoethanol Roth, Karlsruhe 
Blotting Filter Paper Bio-Rad, München 
Bovine serum albumin (BSA) 
PAA Laboratories GmbH, 
Pasching 
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Bovine Donor Serum 
Gibco, 
Invitrogen,Karlsruhe 
Bromophenol blue 
Sigma-Aldrich, 
Taufkirchen 
Cell culture plastic ware (flasks and dishes) 
Greiner Bio-One, 
Frickenhausen 
Coelenterazine 
Sigma-Aldrich, 
Taufkirchen 
p-Coumaric Acid 
Sigma-Aldrich, 
Taufkirchen 
Crystal Violet (certified by the Biological 
Stain Commission) 
Sigma-Aldrich, 
Taufkirchen 
Cycloheximide Serva, Heidelberg 
Dimethylsulfoxide (DMSO) Roth, Karlsruhe 
Dithiothreitol (DTT) Roth, Karlsruhe 
6×DNA loading dye PeqLab, Erlangen 
dNTP 
Mix Long Range 
Peqlab,Erlangen 
Draq5 
BioStatus Limited, 
Shepshed 
(UK) 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Invitrogen, Karlsruhe 
Ethanol Roth, Karlsruhe 
Ethidium Bromide Roth, Karlsruhe 
Etoposide 
Sigma-Aldrich, 
Taufkirchen 
EthylenediamineTetraacetic Acid (EDTA) 
 
Roth, Karlsruhe 
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Ethylene glycol-bis(2-aminoethylether)- 
N,N,N′,N′-tetra acetic acid (EGTA) 
Roth, Karlsruhe 
Foetal Bovine Serum (FBS) PAA, Pasching, Austria 
Formaldehyde Merck, Darmstadt 
G418, Geneticin® 
Thermo Fisher Scientific, 
(Karlsruhe) GmbH. 
Glucose Roth, Karlsruhe 
Glutathione sepharose 4B GE Healthcare, Dharmacon 
L-Glutathione Roth, Karlsruhe 
Glycerol Roth, Karlsruhe 
Glycyl-glycine (Gly-Gly) 
Sigma-Aldrich, 
Taufkirchen 
Guanidinium-HCL 
Sigma Aldrich, 
Taufkirchen 
HEPES (4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid)) 
Roth, Karlsruhe 
Hydrogen Chloride (HCl) Roth, Karlsruhe 
Hydrogen Peroxide (H2O2) Roth, Karlsruhe 
Hydroxyurea 
Sigma Aldrich, 
Taufkirchen 
Igepal CA-630 (Nonident P-40 (NP40)) Roth, Karlsruhe 
Imidazole 
Sigma Aldrich, 
Taufkirchen 
Immun-Blot
®
 PVDF Bio-Rad, München 
ImmunoPureR Immobilized Protein A 
Pierce, Thermo Scientific, 
Rockford (USA) 
ImmunoPureR Immobilized Protein G 
Pierce, Thermo Scientific, 
Rockford (USA) 
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Iodoacetamide 
Sigma Aldrich, 
Taufkirchen 
Ink Pelikan, Hannover 
Isopropanol Roth, Karlsruhe 
Luminol sodium salt Roth, Karlsruhe 
Luciferase Substrate Promega, Mannheim 
Lysozyme Roth, Karlsruhe 
Magnesium carbonate (MgCO3) Roth, Karlsruhe 
Magnesium Chloride (MgCl2) Roth, Karlsruhe 
Magnesium Sulfate (MgSO4) 
Sigma Aldrich, 
Taufkirchen 
Methanol Roth, Karlsruhe 
Methyl methanesulfonate (MMS) 
Fluka Chemical GmbH, 
Switzerland 
β-mercaptoethanol Roth, Karlsruhe 
MG132 
Calbiochem, Darmstadt, 
Germany 
N,N,N’,N’Tetramethylethylenediamine 
(TEMED) 
Roth, Karlsruhe 
Ni
2+
nitrilotriacetic acid (Ni-NTA)-agarose Qiagen Hilden, Germany 
Parafilm M Brand, Wertheim 
Passive Lysis Buffer 
 
Promega, Mannheim 
 
PCR plate and PCR clear seal Steinbrenner, Wiesenbach 
Penicillin/Streptomycin Invitrogen, Karlsruhe 
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Petri dishes 
Greiner Bio-One, 
Frickenhausen, Germany 
1,10-Phenanthroline 
Sigma Aldrich, 
Taufkirchen 
Phenylmethanesulfonyl fluoride (PMSF) 
Sigma Aldrich, 
Taufkirchen 
Phosphostop Phosphatase Inhibitor Cocktail Roche, Grenzach 
Phosphate buffered saline (PBS) Invitrogen, Karlsruhe 
Pipette tips Brand, Wertheim 
Potassium Chloride (KCl) Roth, Karlsruhe 
Potassium dihydrogen phosphate (KH2PO4) Roth, Karlsruhe 
Puromycin 
Sigma Aldrich, 
Taufkirchen 
QuantiTect Green PCR SYBR Qiagen, Hilden, Germany 
Reaction tubes (1.5 ml and 2 ml) Eppendorf, Hamburg 
Reaction tubes (15 ml and 50 ml) 
Greiner Bio-One, 
Frickenhausen 
Rotiphorese Gel 30: Acrylmide/bis- 
Acrylamide 
Roth, Karlsruhe 
Roti®-Free Stripping Buffer 2.2 plus Roth, Karlsruhe 
Roti®-Quant(Protein quantitation assay 
according to Bradford) 
Roth, Karlsruhe 
RNase Inhibitor (rRNasin) 
 
Promega, Mannheim 
 
ScreenFect® 
ScreenFect GmbH, 
Karlsruhe 
Skimmed milk powder Saliter, Obergünzburg 
Sodium acetate (NaAc) Roth, Karlsruhe 
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Sodium bicarbonate (NaHCO3) Roth, Karlsruhe 
Sodium chloride (NaCl) Roth, Karlsruhe 
Sodium deoxycholate. Roth, Karlsruhe 
Sodium dihydrogen phosphate(NaH2PO4) Roth, Karlsruhe 
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe 
Sodium hydrogen phosphate (Na2HPO4) Roth, Karlsruhe 
Sodium Hydroxide (NaOH) Roth, Karlsruhe 
Sucrose Roth, Karlsruhe 
Syringes and needles B. Braun, Melsungen 
Thio-urea Roth, Karlsruhe 
Trichloroacetic acid (TCA) 
Sigma-Aldrich, 
Taufkirchen 
Tris-base Roth, Karlsruhe 
Triton X-100 Roth, Karlsruhe 
Tryptone/Peptone Roth, Karlsruhe 
Tween 20 
Sigma Aldrich, 
Taufkirchen 
Urea Roth, Karlsruhe 
White flat-bottomed96-well plate 
Greiner, Tecan, Salzburg, 
Austaria 
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2.1.2 Enzymes 
Enzyme Source 
  
DNase I Promega, Mannheim 
  
M-MLV Reverse Transcriptase, RNase H(-) Promega, Mannheim 
  
Restriction enzymes: BamHI, NotI and XhoI 
Fermentas, St Leon-Rot, 
Germany  
  
RNase-A Invitrogen, Karlsruhe 
  
T4 DNA Ligase Promega, Mannheim 
  
0.25% Trypsin-EDTA Invitrogen, Karlsruhe 
  
GoTaq® G2 DNA Polymerase Promega, Mannheim 
  
PrimeStar DNA polymerase Promega, Mannheim 
  
2.1.3 Kits 
KIT Source 
QIAGEN Plasmid Maxi kit(plasmid 
purification) 
Qiagen, Hilden, Germany 
QIAprep Spin Miniprep Kit (plasmid 
purification) Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
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2.1.4 Oligonucleotides 
2.1.4.1 Primers 
All primers were synthesized by Metabion (Martinsried, Germany). 
2.1.4.1.1 Primers for cloning 
Primer Sequence 
Fam83F-NotI-F 
5′-CTT GCG GCC GCG ATG GCC GAG TCC 
CAG CTG AAC-3′ 
Fam83F-Flag-BamHI-R 
5′-CGG GAT CCT CAG GAA ATC ACA CAG 
TTG CTA G-3′ 
Fam83F-BamHI-F 
5′-CTT GGA TCC GAT GGC CGA GTC CCA 
GCT GAA C-3′ 
Fam83F-Flag-R-1 
5′-CTT GCG GCC GCT TAT TTA TCA TCA 
TCA TCT TTA TAA TCA AAG GGC TCT 
ACG TTC TG-3′ 
Fam83F-Flag-R-2 
5′-CTT GCG GCC GCT TAT TTA TCA TCA 
TCA TCT TTA TCC TCT CCC AAG GGG ATG 
GGC T-3′ 
GST-Fam83F-BamHI-F 
5′-CCG CGT GGA TCC CCA ATG GCC GAG 
TCC CAG CTG AAC TGC-3′ 
GST-Fam83F-XhoI-R 
5′-CCG CTC GAG TCA GGA AAT CAC ACA 
GTT GCT AG-3′ 
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2.1.4.1.2 Primers for qRT-PCR 
Primer Sequence 
RT-β-Actin- Forward 5′- CCAACCGCGAGAAGATGA-3′ 
RT-β-Actin- Reverse 5′- CCAGAGGCGTACAGGGATAG-3′ 
RT-Mdm2- Forward 5′- TGGAGTCCCGAGTTTCTCTG-3′ 
RT- Mdm2- Reverse 5′- AGCCACTAAATTTCTGTAGATCATTG-3′ 
RT-P53- Forward 5′- CCCCAGCCAAAGAAGAAAC-3′ 
RT- P53- Reverse 5′- AACATCTCGAAGCGCTCAC-3′ 
RT-Fam83F-Forward 5′-CGTCGGCTTCTACATGCCC-3′ 
RT-Fam83F-Reverse 5′-GCTCTACGTTCTGTCCTGTCA-3′ 
2.1.4.2 Lentiviruses carrying shRNAs 
All lentiviruses were produced by Sigma Aldrich, Saint Louis Missouri, USA. 
Name TRC number Clone ID Sequence 
Control 
shRNA 
SHCO16V-
1EA 
 
MISSION® pLKO.1-puro non -
target shRNA control 
transduction particles targets no 
known genes from any species 
Fam83F 
shRNA 
TRCN-
0000434615 
NM_138435.2
-1667s21c1 
5′-CCG GGT CGC ACA CTG 
CAC CAG TTT GCT CGA 
GCA AAC TGG TGC AGT 
GTG CGA CTT TTT TG-3′ 
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2.1.5 Bacteria 
Name Genotype 
BL21 (DE3) 
E. coli F
-
ompT gal hsdSB (rB
-
mB
+) λ (DE3[lacI 
lacUV5-  T7 gene l indl sam7 nin5]) 
DH5α 
E. coli F- and A1 glnV44thi-1 recA1 relA1 gyrA96 
deoRnupG Φ80dlacZΔM15 Δ(lacZYA-argF) U169, 
hsdR17(rk
-
mk
+), λ 
2.1.6 Eukaryotic cells and cell lines 
Cell line Origin 
P53 
status 
Culture 
medium 
    
GM38 Human normal skin fibroblast wild type 
DMEM + 15% 
FCS 
H1299 
Human non-small cell lung 
Carcinoma 
Null 
DMEM + 10% 
FCS 
MCF7 
Human breast 
adenocarcinoma cell line 
wild type 
DMEM + 10% 
FCS 
RKO Human colon carcinoma wild type 
DMEM + 10% 
FCS 
2.1.7 Plasmids 
Name Description 
pBluescriptR-FAM83F 
Vector containing the human FAM83F 
coding sequence (Thermo Scientific)  
pcDNA3 Mammalian Expression Vector (Invitrogen) 
P3xFLAG-CMV
TM
 7.1 Mammalian Expression Vector (Invitrogen) 
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His-Ubiquitin 
Expression plasmid containing the cDNA of 
His-Ubiquitin carrying a 6x His-tag, 
(provided by Sibylle Mittnacht) 
pcDNA3-Mdm2 Expression plasmid containing the cDNA of 
murine Mdm2 (provided by Arnold Levine) 
pcDNA3-p53 Expression plasmid containing the cDNA of 
P53 
pcDNA3-p53-R273H 
Expression plasmid containing the cDNA of 
mutant P53 where the arginine 273 was 
replaced by histidine 
pcDNA3-p53-R175H 
Expression plasmid containing the cDNA of 
mutant P53 where the arginine 175 was 
replaced by histidine 
Flag Fam83F Expression plasmid containing the cDNA of 
FLAG- tagged human FAM83F 
Flag Fam83F Δ-1 
Expression plasmid containing the cDNA of 
FLAG- tagged human FAM83F deletion 
mutant (aa 1-397) 
Flag Fam83F Δ-2 
Expression plasmid containing the cDNA of 
FLAG- tagged human FAM83F deletion 
mutant (aa 1-265) 
V5-p53 Expression plasmid containing the cDNA 
ofV5 tagged human p53 
V5-p53Δ-1 
Expression plasmid containing the cDNA 
ofV5 tagged human p53 deletion mutant (aa 
1-300) 
V5-p53Δ-2 
Expression plasmid containing the cDNA 
ofV5 tagged human p53 deletion mutant (aa 
1-160) 
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2.1.8 Antibodies 
2.1.8.1 Primary antibodies 
Target Description Source 
Bax Rabbit, polyclonal 
Cell Signalling, 
Danvers, USA 
Fam83F (K18) Rabbit, polyclonal Santa Cruz, Heidelberg 
Flag (F3165) Mouse, monoclonal 
Sigma-Aldrich, 
Taufkirchen 
Flag (DYKDDDDK) 
Affinity gel 
Mouse, monoclonal Biotool (Biotool.com) 
GAPDH 
(Glyceraldehyde-3- 
phosphate 
dehydrogenase) (6C5) 
Mouse, Monoclonal HyTest, Turku, Finland 
HA Rat, Monoclonal 
Roche Diagnostics, 
USA 
Histone-H3 (C16)(sc- 
8654) 
Goat, Polyclonal Santa Cruz, Heidelberg 
MDM2 (4B2) Mouse, Monoclonal 
Calbiochem, Merck, 
Darmstadt 
P21 Mouse, Monoclonal BD Pharmigen 
TM 
P53(Ab-2) Mouse, Monoclonal 
Calbiochem, Merck, 
Darmstadt 
P53 (DO-1) Mouse, Monoclonal Santa Cruz, Heidelberg 
PCNA (PC10) Mouse, Monoclonal Santa Cruz, Heidelberg 
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V5 Mouse, Monoclonal Serotec 
Normal mouse IgG 
(control IgG) 
Mouse, polyclonal Santa Cruz, Heidelberg 
Normal rabbit IgG 
(control IgG) 
Rabbit, polyclonal Santa Cruz, Heidelberg 
2.1.8.2 Secondary antibodies 
Secondary antibody Source 
Alexa Fluor 488 goat anti-mouse IgG Invitrogen, Karlsruhe 
Alexa Fluor 546 goat anti-rabbit IgG Invitrogen, Karlsruhe 
Clean-Blot™ IP Detection Reagent (HRP) 
ThermoFisher Scientific 
(Karlsruhe) GmbH 
Rabbit anti-goat IgG/HRP Dako, Glostrup (Dennmark) 
Goat anti-mouse IgG/HRP Dako, Glostrup (Dennmark) 
Goat anti-rabbit IgG/HRP Dako, Glostrup (Dennmark) 
2.1.9 Size standards 
Name Source 
Peq-GOLD Protein Marker IV Peqlab, Erlangen 
Peq-GOLD 100bp DNA-Ladder-Mix Peqlab, Erlangen 
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2.1.10 Instruments and glassware 
Name Source 
Analytical balance Mettler Toledo, Gießen 
Bioruptor 
®
 sonication device Diagenode, Liege (Belgium) 
Cell culture centrifuge for 15/50 ml 
Falcons 
Universal 320, Centrifuge, 
Hettich 
Cell culture incubator Heraeus, Fellbach 
ChemiDoc, Touch, imaging system 
Bio-Rad, Laboratories GmbH, 
München 
Clean bench W. H. Mahl, Trendelburg 
Cold room (4 ºC) Foster, Schutterwald 
Cold room (-20 ºC) Foster, Schutterwald 
Cooling centrifuge Biofuge Primo R for 
15/50 ml falcons 
Heraeus, Fellbach 
Cooling centrifuge Eppendorf 5417 R for 
PCR tube 
Eppendorf, Hamburg 
Cooling microcentrifuge Heraeus 
Fresco17 
Thermo Scientific, Waltham 
(USA) 
Corex
®
 Centrifuge Tubes Corex (USA) 
Covaris
TM
 S220 focused ultrasonicator 
Thermo Scientific, Waltham 
(USA) 
Electrophoresis equipment (SDS-PAGE) Bio-Rad, München 
Electrophoresis Power Supply PeqLab, Erlangen 
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ELx 808IU Ultra Microplate (ELISA) 
Reader 
Bio-Tek Instruments, Bad 
Friedrichshall 
End-over-end rotator Heidolph, Schwabach 
EttanIPGphor II Isoelectric Focusing 
System 
GE Healthcare, Freiberg 
Floor centrifuge Beckman Avanti J-20 Beckman Coulter, Krefeld 
Freezer (-20 
o
C) Liebherr, Ochsenhausen 
Freezer (-80 
o
C) 
New Brunswick Scientific, 
Edison (USA) 
Glass pipettes Brand, Wertheim 
Glassware (Erlenmeyer flasks, beakers, 
bottles) 
Scott, Mainz 
Hamilton syringe Hamilton, Martinsried 
High speed floor centrifuge Avanti J2-HS Beckman Coulter, Krefeld 
Horizontal nucleic acid electrophoresis 
System 
Bio-Rad, München 
Inverted microscope Leica, Wetzlar 
KODAK  X-OMAT  2000  X-ray  film 
Processor 
Kodak, Stuttgart 
Laboratory balance Sartorius, Göttingen 
Luminometer plate reader 
Perkin Elmer 1420 
Luminescence Counter Victor 
3v, Finland 
Magnetic stirrer IKA Labortechnik, Stauffen 
Measuring cylinders (10 ml, 25 ml, 50 
ml,100 ml, 250 ml, 500 ml, 1000 ml, 
2000ml) 
Brand, Wertheim 
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MicrocentrifugeHeraeus Pico 21 
Thermo Scientific, Waltham 
(USA) 
NanoDrop ND-1000 Spectrophotometer 
Marienfeld, Lauda 
Königshofen 
Neubauer counting chamber 
Marienfeld, Lauda-
Königshofen 
PCR thermocycler Bio-Rad, München 
Pipettes (2-20μl, 20-200μl, 200-1000μl) Gilson, Middleton (USA) 
Pipette Aid Brand, Wertheim 
Platform shaker Heidolph, Schwabach 
Real-time PCR System StepOnePlus 
Applied Biosystems, 
Darmstadt 
Refrigerator (4
o
C) Liebherr, Ochsenhausen 
Shaker for Eppendorf tubes Eppendorf, Hamburg 
Test-tube rotator Kisker, Steinfurt 
Thermo-mixer Eppendorf, Hamburg 
Trans-Blot
®
 Turbo 
TM
 Transfer System Bio-Rad, München 
UV transilluminator PeqLab, Erlangen 
Vortex mixer Julabo, Seelbach 
Water bath-19L Köttermann GmbH & Co KG 
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2.1.11 Software 
Name Version/Description 
Image-J version 1.45s 
Image-lab version 5.2.1 
KC4™ Data Analysis version 3.01 
Zeiss LSM Image Browser version 4.2.0.121 
2.1.12 Data Bases 
Name Source 
Human Genome Assemblys NCBI 
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2.2 Methods 
2.2.1 Cell culture and treatment 
2.2.1.1 Culture of human cells 
The cell lines and their respective culture media are listed in table 2.1.6. The cell 
culture medium was supplemented with fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. The cells were cultured in sterile Cellstar® cell culture 
dishes at 37°C and 5% CO2 in a humidified atmosphere. For sub-culturing, cells 
were detached from the culture dish by trypsinization. Therefore, the culture medium 
was removed from the cells. The cells were then washed with PBS. Trypsin/EDTA 
was added and incubated until the cells were detached. Trypsinization was stopped 
by the addition of complete growth medium. Then the cells were pelleted for 2 min 
at 1200 rpm. The cells were suspended in complete growth medium and a part of the 
cells was transferred to a new culture dish. 
2.2.1.2 Treatment of cells 
For UV irradiation, the medium was removed from the culture dish. The cells were 
washed with PBS and irradiated with 30 J/m
2
 UVC light. After irradiation, the 
original culture medium was added back to the cells.  
Hydroxyurea was dissolved in H2O and used at a final concentration of 1.5 mM. 
MG132 was dissolved in DMSO and used at a final concentration of 20 μM. 
Cycloheximide was dissolved in H2O and used at a final concentration of 100 μg/ml. 
G418 was dissolved in complete growth medium and used at a final concentration of 
500 mg/ml. Etoposide was dissolved in DMSO and used at a final concentration of 
50 μM. Methylmethansulfonate was dissolved in H2O and used at a final 
concentration of 5 mM. 
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2.2.1.3 Transfection of cells 
H1299 cells were transfected by DNA-calcium phosphate co-precipitation. By this 
method, DNA is complexed with the calcium phosphate. The crystals precipitate on 
the cells and are taken up by the cells by endocytosis. 
 All solutions were prepared with ultrapure water and sterile equipment. First the 
required amount of DNA was mixed with the appropriate amount of water. Then 
CaCl2 was added to a final concentration of 0.125 M. 2X HEPES-buffered saline 
(280 mM NaCl, 1.5 mM Na2HPO4, 50 mM HEPES pH 7.05) was added to a final 
concentration of 1X under constant mixing. Afterwards, the cell suspension was 
mixed with the transfection mix, transferred to a culture dish and incubated 
overnight. After 24 hours, the transfection medium was removed and 15% glycerol 
in PBS was added. The glycerol solution was incubated for 3 minutes. The cells 
were washed with PBS before complete culture medium was added to the cells. 
MCF7 cells were transfected with ScreenFect® according to the manufacturer’s 
recommendation. 6 μl transfection reagent were diluted with 150 μl dilution buffer 
and incubated 2-5 min at room temperature. Then 150 ng DNA were mixed with 150 
μl dilution buffer. Thereafter, the diluted DNA was mixed with the diluted 
transfection reagent and incubated for 20 minutes at room temperature. During the 
incubation time, cells were trypsinized and counted. 5x10
5
 cells were seeded in 24-
well plates. The DNA/transfection mixture was pipetted onto the cells and the cells 
were incubated for 48 hours. 
2.2.1.4 Infection of cells with lentiviruses 
1.6 x 10
4
 RKO cells were seeded in a well of a 96-well plate. The next day, the 
culture medium was replaced with 110 μl of normal growth medium. Lentiviruses 
were added at 0.5, 1, 2 and 5 multiplicity of infection (MOI). The next day, the 
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medium was replaced with 100 μl of fresh normal growth medium. The next day, 
puromycin was added to a final concentration of 0.5 μg/ml. Surviving cells were 
expanded with complete growth medium containing puromycin. 
2.2.1.5 Cell proliferation assay 
1 x 10
4
 cells were seeded in a well of a 24-well plate in triplicates and incubated 
under normal growth conditions. 0, 24, 48 and 72 hours after seeding, cells were 
counted. Therefore, cells were trypsinized with 0.5 ml trypsin. Trypsinization was 
stopped by addition of 2 ml complete growth medium. 10 μl of the cell suspension 
were pipetted into a Neubauer counting chamber and counted. 
2.2.1.6 Colony forming assay 
The colony forming assay was used to measure the clonogenic cell survival. This 
assay is based on the ability of a single cell to undergo several successive divisions 
(at least 5-6) and grow into a colony. H1299 cells were transfected with plasmids 
encoding Mdm2 and p53 together with a plasmid encoding FAM83F or with the 
empty vector pCDNA3, 48 hours after transfection, fresh growth medium was added 
and the cells were treated with G418 (500 mg/ml final concentration) for 2 weeks. 
Then the medium was aspirated and the colonies were fixed in 1% methanol for 20 
minutes at room temperature. The colonies were visualized by staining with crystal 
violet blue for 15 minutes at room temperature. The cells were washed with PBS 
until the excess dye was removed. The colonies were counted by using the image-J 
program. 
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2.2.2 Protein Methods 
2.2.2.1 Immunofluorescence staining  
For immunofluorescence staining, cells were plated onto autoclaved cover slips. 48 
hours after transfection, the medium was removed, the cells were washed with PBS 
and incubated with ice cold acetone/methanol (1:1) for 8 minutes on ice. After 
washing with PBS, the cells were blocked for 30 minutes at room temperature with 
blocking solution (1% goat serum, 1% bovine serum albumin in PBS). The primary 
antibody solution containing the DO1 anti-p53 antibody (mouse, monoclonal) 
diluted 1:500 and the anti-FAM83F antibody (rabbit polyclonal) diluted 1:500 was 
added and incubated overnight at 4°C. The samples were washed 3 times for 5 
minutes with PBS. Then the secondary antibody solution containing the Alexa-488 
coupled anti-rabbit antibody, diluted 1:500, and the Alexa-546 coupled anti-mouse 
antibody, diluted 1:500, was added together with Draq5 and diluted 1:1000. After 1 
hour incubation in the dark at room temperature, the cells were washed three times 
with PBS and mounted onto microscope slides with Aqua-Poly/Mount. The slides 
were dried overnight and analysed with a Leica confocal microscope. 
2.2.2.2 SDS-PAGE and Western Blotting 
2.2.2.2.1 Preparation of cell lysates 
The culture medium was aspirated from the cells, the cells were washed with cold 
PBS and scraped from the culture dish. The cell suspension was transferred to a 
reaction tube and the cells were pelleted by centrifugation at 1200 rpm for 5 minutes. 
The cell pellet was suspended in 1% NP40 lysis buffer (50 mM Tis pH 8.0, 150 mM 
NaCl, 5 mM EDTA, 1% NP40, 1 mM PMSF) and incubated for 10 minutes on ice. 
The lysate was cleared by centrifugation at 1300 for 10 minutes at 4°C. The 
supernatant was transferred to a fresh reaction tube and the protein concentration 
was determined. 
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2.2.2.2.2 Bradford assay 
The Bradford assay was used to determine the protein concentration. Therefore, the 
Roti®-Quant protein quantitation assay solution was diluted 1:5. Next, a standard 
curve was established. Therefore, 0, 2, 4 and 6 μl of a BSA solution (1 mg/ml) were 
mixed with 500 μl of the Roti®-Quant protein quantitation Assay solution. Then 2 μl 
of the cell lysate was also mixed with 500 μl with the Roti®-Quant protein 
quantitation Assay solution. 150 μl of these mixtures were pipetted into the wells of 
a 96-well plate and the absorbance was measured at λ595 nm. The standard curve 
was used to determine the concentration of the protein lysates. 
2.2.2.2.3 Separation of proteins by SDS-PAGE 
Cellular proteins can be separated on the basis of their mass by electrophoresis. For 
SDS-polyacrylamide gel electrophoresis, gel solutions were poured between two 
glass plates, a longer and a shorter one that were separated by spacers and fixed in a 
casting stand. First, the separating gel, that separates the proteins according to size, 
was poured. Therefore a 10% acrylamide gel solution (10% acrylamide, 375 mM 
Tris pH 8.8, 0.1% SDS, 0.1% APS, 0.04% TEMED) was prepared and poured 
between the two glass plates. 300 μl ethanol were carefully pipetted over the 
separating gel and the gel was allowed to polymerize. Then the ethanol was removed 
and a 5% stacking gel solution (5% acrylamide, 125 mM Tris pH 6.8, 0.1% SDS, 
0.1% APS, 0.1% TEMED) was prepared and poured over the separating gel. A comb 
was inserted to allow the formation of pockets into which the samples could be 
loaded later. After polymerization of the stacking gel, the glass plates with the gel 
were inserted into an electrophoreses chamber that was filled with running buffer 
(193 mM glycine, 24 mM Tris pH 6.8, 0.1% SDS) and electrophoresis was carried 
out at 120V. 
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2.2.2.2.4 Western Blotting and Immunedetection 
After separating the protein samples by SDS-PAGE, they were transferred to a 
polyvinolidene fluoride membrane. Therefore, the membrane was first rinsed with 
methanol and then equilibrated with transfer buffer (0.193 M Glycine, 0.043 M Tris 
base, 10% methanol). Four pieces of filter paper and two transfer sponges were also 
soaked in transfer buffer. The membrane and gel was assembled in the blotting 
sandwich so that blot and membrane are in the centre. On each side of blot and 
membrane were two filter papers and a transfer sponge. All air bubbles were 
removed and the sandwich was placed into the transfer chamber. Thereby the side 
with the gel was located at the side of the cathode so that the negatively loaded 
proteins move towards the membrane. The chamber was filled with transfer buffer 
and the transfer was performed at 30V overnight.  
The next day, the membrane was blocked in blocking solution (5% milk powder in 
PBS/0.02% Tween-20) for 1 hour. After blocking, the membrane was incubated over 
night at 4°C with a specific primary antibody. The next day, the membrane was 
washed three times with PBS/0.02% Tween-20 for 5 min each. Afterwards, the 
membrane was incubated with a horseradish peroxidase-coupled secondary antibody 
diluted 1:2000 in DMSO/10% FCS four 1 hour at room temperature. Thereafter, the 
Western blot was developed. A mixture of equal volumes of ECL (enhancer of 
chemioluminenscence) solution I (2.5 mM luminol, 0.396 mM coumaric acid, 225 
mM Tris pH 8.5) and ECL solution II (0.0192% H2O2, 225 mM Tris pH 8.5) was 
poured over the membrane and incubated for 5 seconds. Thereafter, the membrane 
was wrapped into plastic foil and exposed against an X-ray film. 
2.2.2.3 Immunoprecipitation  
Cells were washed with ice-cold PBS and lysed with cold 0.5% NP-40 lysis buffer 
(50 mM Tris pH 8, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM PMSF) and 
were incubated for 15 min on ice. The lysates were centrifuged at 13.000 rpm for 15 
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min at 4°C. The supernatant was transferred into a fresh tube. 5% of the protein 
lysate were kept for input control. The remaining cellular lysate was incubated with 
the desired antibody coupled to a mixture of protein A-sepharose and protein G-
sepharose (4:1) overnight at 4°C with end-over-end rotation. Thereafter, the 
sepharose was washed 3 times with 0.5% NP-40 buffer. After the last wash were the 
precipitates suspended in 2X sample buffer, vortexed and heated for 10 min to 95°C. 
The samples were stored at -20°C. 
2.2.2.4 Co-Immunoprecipitation  
For co-immunoprecipitations, the cells were lysed in cold CoIP-buffer (50 mM Tris 
pH8, 5 mM EDTA, 150 mM NaCl, 0.5% NP-40, 1 mM PMSF) for 15 min on ice. 
The lysates were cleared by centrifugation at 13.000 rpm for 15 min at 4°C. The 
supernatant was transferred into a fresh tube and pre-cleared with 50 μl protein A-
sepharose for 1 h at 4°C with end-over-end rotation. Thereafter, 5% of the protein 
lysate was kept for input control. The desired antibody was coupled to protein A 
sepharose, added to the remaining cellular lysate and incubated overnight at 4°C 
with end-over-end rotation. The next day, the sepharose was washed 3 times with 
CoIP-buffer. After the last wash were the precipitates suspended in 2X sample 
buffer, vortexed and heated for 10 min to 95°C. The samples were stored at -20°C. 
2.2.2.5 GST-Pulldown Assay 
The GST-Fam83F fusion protein was purified from a culture of E.coli BL21 cells 
that had been transformed with a plasmid encoding the gene for it. The bacteria were 
grown in LB medium (10 g/l Tryptone, 5 g/l Yeast extract, 10 g/l NaCl) overnight at 
37°C with shaking. The next morning, the overnight culture was diluted with LB 
medium and IPTG was added to a final concentration of 100 μM. After culturing the 
bacteria for 6 h at room temperature with constant vigorous shaking, the bacteria 
were collected by centrifugation at 6,000 rpm for 15 min at 4°C and stored at -80°C 
until they were further processed.  
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The cell pellet was lysed in lysis buffer (1% Triton-X-100, 1 mM PMSF in PBS), 
briefly sonicated and incubated in ice for 30 min. The insoluble material was 
removed by centrifugation at 10,000 rpm at 4°C for 30 min. Thereafter, the clarified 
lysate was mixed with 500 μl glutathione-sepharose for 4 h at 4°C by end-over-end 
rotation. The sepharose was washed 6 times with lysis buffer and the GST-protein 
was eluted with GST-elution buffer (10 mM reduced glutathione, 50 mM Tris pH8). 
The expression of the purified protein was tested by SDS-PAGE.  
10 μg of the eluted GST-Fam83F were mixed with 10 μg His-tagged p53, also 
expressed in bacteria and purified, and diluted with pulldown buffer (10 mM HEPES 
pH 7.9, 50 mM NaCl, 0.5 M sucrose, 0.5% Triton-X-100). 10% of the mixture was 
taken for input control. To the rest of the lysate were 30 μl glutathione-sepharose 
added and the mixture was incubated overnight at 4°C with end-over-end rotation. 
The next day, the sepharose was washed 3 times with pulldown-buffer. After the last 
wash were the precipitates suspended in 2X sample buffer, vortexed, heated for 10 
min to 95°C and further analysed by Western Blotting. 
2.2.2.6 Cell Fractionation  
Cells were washed with ice-cold PBS, scraped from the dish and collected by 
centrifugation at 2000 rpm for 5 min. Then the pellet was washed in 400 μl cold 
buffer A (10 mM HEPES pH 7.5, 10 mM KCl, 0.1 mM EGTA and 0.1 mM EDTA). 
The supernatant was removed and the pellet was suspended in 400 μl fresh buffer A 
and incubated for 15 min on ice to allow swelling of the cells. 25 μl of a 10% 
solution of NP-40 were added, the sample was vortexed vigorously and centrifuged 
for 1 min at 13,000 rpm. The supernatant, containing the cytoplasmic fraction was 
transferred into a new tube. The pellet, containing the nuclei, was suspended in 150 
μl cold buffer C (20 mM HEPES pH7.5, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM 
EDTA and 25% glycerol) and incubated on ice for 20 min with periodical vigorous 
vortexing. The nuclear lysate was collected by centrifugation for 5 min at 13,000 
rpm. Cytoplasmic and nuclear fractions were used immediately for SDS-PAGE or 
stored at -20°C for short time intervals. 
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2.2.2.7 Ubiquitination assay 
H1299 cells were transfected with plasmids encoding His-tagged ubiquitin, Mdm2 
and p53 together with a plasmid encoding Fam83F or with vector DNA. 24 h after 
transfection, cells were treated for 6 h with 20 μM MG132 to increase the amount of 
ubiquitinated proteins.  
The cells were washed with ice cold PBS and suspended in PBS. 10% of the cell 
suspension was kept for input control and lysed in NP-40 buffer as described above. 
The remaining cells were collected by centrifugation for 5 min at 2,000 rpm and 
lysed in guanidinium lysis buffer pH8 (6 M guanidinium HCl, 0.1 M 
Na2HPO4/NaH2PO4 pH8, 0.01 M Tris pH8, 5 mM imidazole, 10 mM β- 
mercaptoethanol). Ni
2+
-nitrilotriacetic acid (Ni-NTA)-agarose was added to the 
lysate and the mixture was incubated overnight at room temperature with end-over- 
end rotation. The next day, the agarose was pelleted by centrifugation at 2,000 rpm 
for 5 min followed by washing. The agarose was subsequently washed with 
guanidinium buffer, urea buffer pH8 (8 M urea, 0.1 M Na2HPO4/NaH2PO4 pH8, 
0.01 M Tris pH8, 10 mM β-mercaptoethanol), buffer A pH6.3 (8 M urea, 0.1 M 
Na2HPO4/NaH2PO4 pH6.3, 0.01 M Tris pH6.3, 10 mM β-mercaptoethanol), buffer A 
plus 0.2% Triton-X-100 and with buffer A plus 0.1% Triton-X-100. The 
ubiqutinated proteins were eluted with elution buffer (60 mM imidazole. 5% SDS, 
0.15 M Tris pH6.8, 30% glycerol, 0.72 M β-mercaptoethanol). The eluate was mixed 
with 2x SDS-PAGE (1:1), vortexed, heated to 95°C for 5 min and loaded onto a 
SDS-PAGE gel. 
2.2.2.8 Luciferase Assay 
Cells were seeded into a 96-well plate and transfected with 50 ng of a plasmid 
encoding the p53-dependent reporter PG13 and with 5 ng of a plasmid encoding 
renilla luciferase together with a plasmid encoding Fam83F or with empty vector. 48 
h after transfection, cells were lysed in passive lysis buffer (Promega) and 
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transferred to -80° for 4 hours. The luminometer (Perkin Elmer, VictorLight 1420) 
was programmed for the appropriate delay and measurement times. 
20 μl of the cell extract was pipetted into a well of a white 96-well plate. The plate 
was placed into the luminometer. For renilla activity, the injector added 100 μl of 
renilla substrate (1 μM coelenterazine, 0.5 M NaCl, 1 mM EDTA, 0.1 M potassium 
phosphate buffer pH8) per well and the well was read immediately. For measuring 
Firefly activity added the injector 70 μl of firefly solution I (1 mM ATP, 1mM DTT, 
25 mM Gly-Gly, 15 mM MgSO4, 4 mM EGTA) and 20 μl of the firefly substrate 
solution (200 μM luciferin, 25 mM Gly-Gly, 15 mM MgSO4, 4 mM EGTA). The 
reaction was measured immediately. Reporter activity was calculated by dividing the 
readings for the firefly luciferase by the readings for renilla luciferase. 
2.2.3 Nucleic acid methods 
2.2.3.1 Total RNA extraction 
For the preparation of total RNA was the Quick-RNATM Mini-Prep (Plus) kit 
(Zymo Research, Germany) used.  
H1299 cells were pelleted by centrifugation at 500 g for 1 minute. The supernatant 
was removed and the cell pellet was suspended in RNA lysis buffer. The lysate was 
transferred into a Spin-AwayTM Filter in a collection tube and the sample was 
centrifuged. Then 1 volume ethanol was added to the flow through, mixed well and 
transferred to a Zymo-SpinTM IIICG column in a collection tube. The sample was 
centrifuged again and the flow through was discarded. 700 μl wash buffer were 
added to the column followed by centrifugation and removal of the flow through. 
Then 400 μl RNA wash buffer were added to the column followed by centrifugation 
for 2 minutes to ensure complete removal of the wash buffer. Thereafter, the column 
was transferred into an RNAse-free tube. 100 μl RNAse-free water were added to 
the column matrix and centrifuged. The eluted RNA was used immediately or stored 
at -80°C. 
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2.2.3.2 cDNA synthesis  
For cDNA synthesis was the total mRNA reversely transcribed. At first was the 
RNA for 1 h at 37°C incubated with the RNAse inhibitor Ribo-BlockTM and with 
DNAse I. After DNA digestion, 1 μl of 25 mM EDTA was added to a 20 μl reaction 
and the sample was heated to 65°C for 10 min. Thereafter, 1 μl of a 200 ng/μl 
solution of random primers was added and the mixture was incubated at 70°C for 5 
min. Then 1 μl of the MLVRT (Revert AidTM H Minus MMuLV) was added 
together with 2 μl of a 10 mM solution of dNTPs, 4 μl of a 5x reaction buffer and 4 
μl H2O. The mixture was incubated at 25°C for 10 min followed by 42°C for 60 min 
and 70°C for 10 min. The cDNA was diluted with H2O and stored at -20°C. 
2.2.3.3 Polymerase Chain Reaction for quality control 
After preparing the cDNA, the quality was checked by polymerase chain reaction 
(PCR) using primers for the housekeeping genes (β-Actin). For the PCR, 0.4 μM 
forward and reverse primers, 0.2 mM dNTPs, 2 μl of a 10x GoTaq polymerase 
buffer and 2 μl GoTaq polymerase were mixed with 4 μl of the cDNA. The PCR 
program was set to 95°C for 3 min. Then 30 cycles of 95°C for 30 sec, 60°C for 1 
min and 72°C for 1 min were performed, followed by 10 min at 72°C. The product 
was then analysed by gel electrophoresis. 
2.2.3.4 Agarose gel electrophoresis  
Agarose gel electrophoresis was used to separate DNA fragments. The concentration 
of agarose tanged from 1% to 2% depending on the size of the fragments.  
The agarose was dissolved by boiling in 1x TAE buffer (40 mM Tris pH7.2, 20 mM 
sodium acetate, 1 mM EDTA). The solution was cooled down and ethidium bromide 
was added to a final concentration of 0.4 μg/ml. Thereafter, the solution was poured 
into a horizontal gel chamber and a comb was inserted to allow the formation of 
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slots. After the gel was polymerized, the comb was removed and the gel was 
transferred to an electrophoresis chamber that was filled with 1x TAE buffer. The 
samples were mixed with DNA sample buffer (Peqlab) and pipetted into the slots. 
Electrophoresis was performed at 80-120 V, depending on the size of the gel. The 
DNA fragments were visualized with UV-light. 
2.2.3.5 qRT-PCR 
Quantitative real time PCR (qRT-PCR) was used to determine the relative amounts 
of RNAs.  
4 μl of the cDNA solution were mixed with 10 μl 2x SYBR Green, 1 μl of gene-
specific forward and reverse primers (50 ng/μl) and 4 μl nuclease-free H2O. qRT-
PCR was performed in duplicates. A control was also performed where the template 
was replaced with H2O. The reaction was performed in the ABI StepOnePlus System 
(Applied Biosystems) with the following program: 95°C for 15 sec followed by 40 
cycles of 95°C for 15 sec and 60°C for 30 sec. The reaction was finished by 15 sec at 
95°C, 1 min at 60°C and 15sec at 95°C. The housekeeping gene β-actin was used for 
normalization. 
2.2.3.6 Sub-cloning of Fam83F 
The coding sequence of Flag-Fam83F-∆1, Flag-Fam83F-∆2 and GST-Fam83F was 
amplified from the plasmid encoding full length wild-type Fam83F. The forward 
primer for Flag-Fam83F-∆1 and Flag-Fam83F-∆2 contained a BamHI and the 
reverse primer a NotI restriction site while the forward primer for GST- Fam83F 
contained a BamHI and the reverse primer an XhoI restriction site. 
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2.2.3.6.1 Amplification of the insert 
For the amplification of the insert were 30 cycles of a PCR reaction performed. The 
reaction was done twice to increase the amount of the PCR product. The PCR 
reaction contained 1 μl of template DNA, 1 μl of the Prime Star DNA polymerase, 
0.2 mM dNTPs, 1.5 mM MgSO4, 4 μl of  a 10x Taq buffer and 0.4 μM of the 
forward and reverse primers. The PCR program was set to 95°C for 2 min and 30 
cycles of 95°C for 30 sec, 58°C for 1 min and 72°C for 1 min followed by 5 min at 
72°C. 
2.2.3.6.2 Restriction digest 
The PCR reaction was loaded onto an agarose gel and separated by electrophoresis. 
The Fam83F fragment was excised from the gel and purified using the PeqGold gel 
extraction kit. The purified product was digested with BamH1 and NotI in the case 
of Flag-Fam83F-∆1, Flag-Fam83F-∆2. The pcDNA3 vector into which the 
fragments shall be cloned was digested with the same enzymes. The fragment for 
GST-Fam83F was digested with BamH1 and XhoI and the pGEX-4T-2 vector was 
digested with the same enzymes. Therefore, the PCR fragments and vectors were 
mixed with 1 unit of the restriction enzymes per 1 μg of DNA and the appropriate 
reaction buffer. The digest was performed for 1 h at 37°C. After the digest, the DNA 
fragments and vectors were separated by agarose gel electrophoresis, excised from 
the gel and purified. 
2.2.3.6.3 Purification of DNA by agarose gel electrophoresis 
Gel purification starts with agarose gel electrophoresis that separates DNA by size. 
After electrophoresis, DNA bands were visualized under UV light. The DNA was 
excised, transferred to a 1.5 ml reaction tube and weighted. The purification was 
done by using the PeqGold Gel extraction Kit according to the manufacturer’s 
recommendation. At first, 100 μl binding buffer was added to 100 μg of the weighted 
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agarose piece with the DNA and incubated at 60°C with vortexing until the agarose 
was melted. The solution was transferred to a purification column that was 
connected to a collection tube. The sample was centrifuged for 1 min at 2,000 rpm. 
The flow through was discarded and the column was washed once with 300 μl 
binding buffer followed by washing twice with 500 μl washing buffer. The column 
was centrifuged to remove any residual buffer. For elution was the column 
transferred into a new 1.5 ml tube. 30 μl elution buffer were added to the column, 
incubated for 5 min and centrifuged for 1 min at 2,000 rpm. 
2.2.3.6.4 Ligation of DNA fragments 
All ligations were performed with a T4 DNA ligase. Therefore, two different ratios 
of insert DNA:vector DNA and a negative control without insert were adjusted to    
17 μl with H2O. The sample was mixed with 2 μl 10x ligase buffer and 1 μl T4 
ligase and incubated overnight at 16°C. 
2.2.3.6.5 Transformation of bacteria 
Competent bacteria were transformed with each of the ligation reactions. Therefore, 
100 μl of chemically competent E. coli were incubated with 20 μl of the ligation 
reaction for 30 min on ice followed by a heat-shock at 42°C for 50 sec. Then the mix 
was incubated on ice for 2 min. Thereafter, 900 μl LB medium were added to the 
mix and incubated at 37°C for 1 hour with shaking. In the meantime, an agar plate 
(LB medium, 1 g/l agarose and 100 μg/ml ampicillin) was warmed to room 
temperature. The bacteria were pelleted by centrifugation for 1 min at 8,000 rpm. 
800 μl of the supernatant were aspirated, the bacteria were suspended in the 
remaining 200 μl LB medium, spread over the agar plate and incubated overnight at 
37°C. Positive clones were further amplified. 
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2.2.3.6.6 Purification of plasmids 
Plasmids were purified with the Qiagen plasmid purification kit® according to the 
manufacturer’s recommendation. This protocol is based on a modified alkaline lysis 
procedure followed by binding of the plasmid DNA to a resin. Low molecular 
weight impurities, proteins, RNA and dyes are removed and the plasmid DNA is 
eluted in a high salt buffer. The plasmid is then desalted and concentrated by 
isopropanol precipitation.  
Plasmid preparation starts with the picking of a single colony and inoculation of a 2-
5 ml starter culture in LB medium containing the appropriate selective antibiotic that 
is incubated overnight at 37°C with shaking. The starter culture is then diluted 1/500 
with LB medium containing the appropriate antibiotic and incubated overnight at 
37°C with shaking. The bacteria were harvested by centrifugation at 6,0000 x g for 
15 min at 4°C. The bacterial pellet was suspended in 4 ml buffer P1. Then 4 ml 
buffer P2 were added and carefully mixed by inverting the reaction tube. 4 ml cold 
buffer P3 were added and mixed by inverting the reaction tube. The mixture was 
incubated for 15 min on ice and centrifuged at 4,000 rpm for 10 min at 4°C. The 
supernatant was applied onto a Qiagen column that had been equilibrated with 4 ml 
buffer QBT. The column was washed with 5 ml QC and the DNA was eluted with 4 
ml of buffer QF. The DNA was precipitated by adding 3.5 ml isopropanol and 
collected by centrifugation at 9,000 rpm for 30 min at 4°C. The DNA was washed 
with 70% ethanol and dissolved in TE buffer (10 mM EDTA, 50 mM Tris pH8).  
2.2.3.6.7 Determination of the nucleic acid concentration 
The concentration of nucleic acids was determined by measuring the optical density 
(OD). 2 μl of the nucleic acid were applied onto the Nano-Drop® and analysed with 
the ND-1000 software version 3.1.2. A ratio of OD260/OD280 of 1.8 for DNA (or 
2.0 for RNA) indicates a nucleic acid preparation that is free if protein 
contamination. A ratio of OD260/OD230 above 1.6 indicates that the solution is free 
of organic chemicals and solvents.   
Results 
61 
 
3. Results 
3.1 Fam83F increases p53 levels 
The first observation that Fam83F is a regulator of p53 was made by Ping Zhang 
who identified Fam83F when he was screening a cDNA library for evolutionary 
conserved regulators of p53 (Zhang et al., 2015). In order to confirm his initial 
finding, I overexpressed human Fam83F together with p53 and Mdm2 in the p53- 
negative cell line H1299. I then monitored the abundance of p53, Mdm2 and 
Fam83F by Western Blotting. 
 
 
 
 
Figure 3.1: Overexpression of Fam83F increases p53 abundance. H1299 cells were transfected 
with plasmids encoding Mdm2 and p53 together with a plasmid encoding Fam83F or with vector 
DNA for control. Abundance of p53, Mdm2 and Fam83F was determined by Western Blotting. 
Abundance of PCNA (proliferating cell nuclear antigen) was determined for loading control. 
As shown in figure 3.1, overexpression of Fam83F indeed increased the abundance 
of p53. At the same time, there was no obvious increase in the abundance of Mdm2 
(Figure 3.1).  
p53 is a short-lived protein that is rapidly degraded after its synthesis (Boehme and 
Blattner, 2009). Since Mdm2 is a major regulator of the stability of the p53 protein 
(Haupt et al., 1997; Kubbutat et al., 1997), I wondered whether the induction of p53 
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by Fam83F depends on the presence of Mdm2. To address this question, I 
transfected H1299 cells with plasmids encoding p53 and Fam83F together with a 
plasmid encoding Mdm2, or with vector DNA. 
 
 
 
 
 
Figure 3.2: Induction of p53 by Fam83F requires the presence of Mdm2. H1299 cells were 
transfected with an increasing amount of a plasmid encoding Fam83F together with plasmids 
encoding p53 and Mdm2, or with vector DNA. Abundance of p53, Mdm2, Fam83F and PCNA, for 
loading control, was determined by Western Blotting. 
As shown in Figure 3.2, the increase in p53 abundance caused by Fam83F can only 
be seen in the presence of co-transfected Mdm2. This increase in p53 abundance, 
moreover, correlated strongly with the amount of the plasmid that encodes Fam83F 
that has been transfected (Figure 3.2).  
Regulation of protein stability is a common mechanism by which abundance and 
activity of proteins is controlled. This is also the case for p53 (Ashcroft et al., 1999, 
Ashcroft and Vousden, 1999). 
Since the regulation of p53 by Fam83F depended on Mdm2, I assumed that Fam83F 
might regulate the abundance of p53 by altering its rate of degradation. To address 
this, I transfected H1299 cells with plasmids encoding p53 and Mdm2 together with 
a plasmid encoding Fam83F. Twenty-four hours after transfection, I treated the cells 
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with cycloheximide, an inhibitor of protein biosynthesis (Baliga et al., 1969), and 
harvested cells every fifteen minutes. I then monitored the abundance of p53 by 
Western Blotting. 
 
 
 
 
 
 
 
 
 
Figure 3.3: Fam83F enhances the half-life of p53. (A) H1299 cells were transfected with plasmids 
encoding p53 and Mdm2 and with a plasmid encoding Fam83F or with vector DNA.     24 h after 
transfection, cycloheximide (CHX) were added to a final concentration of 100 μg/ml. Cells were 
harvested at 0, 15, 30 and 45 min after addition of cycloheximide and the abundance of p53 was 
determined by Western Blotting. (B) The signals for p53 and PCNA were quantified and the relative 
abundance of p53 was calculated and blotted. The graph shows mean values and standard deviations 
from 3 independent experiments. The relative amount of p53 at time “0” was set to 100 %. 
As shown in figure 3.3, p53 abundance decreased rabidly when Fam83F was not 
over-expressed. However, when Fam83F was over-expressed, degradation of p53 
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was almost completely prevented (Figure 3.3 A). This can also be seen in the graph 
which also shows a strong extension of the half-life of the p53 protein in the 
presence of over-expressed Fam83F (Figure 3.3 B). This result shows that Fam83F 
increases p53 protein stability. 
In addition to protein stability, the rate of transcription and also the stability of the 
RNA determine how much of a protein is finally available in the cell. Therefore, 
although I could already show that Fam83F regulates protein stability, I wondered 
whether Fam83F also affects the amount of p53 RNA. In order to investigate this, I 
transfected H1299 cells with plasmids encoding p53 and Mdm2 together with a 
plasmid encoding Fam83F or with vector DNA. 
 
Figure 3.4: Fam83F does not induce p53 RNA. H1299 cells were transfected with the indicated 
combinations of plasmids encoding p53, Mdm2 and Fam83F. 24 h after transfection, cells were 
harvested and divided into two parts. (A) One part of the cells was lysed, RNA was prepared and the 
relative abundance of p53 RNA was determined by qRT-PCR. The graph shows mean values and 
standard deviations of 3 independent experiments. The amount of p53 RNA in cells that had only 
been transfected with p53 and vector DNA was set to 1. (B) The second part of the cells was used to 
monitor expression of p53, Mdm2 and Fam83F by Western Blotting. 
Twenty-four hours after transfection, I harvested the cells and divided them into two 
parts. From one part, I purified the RNA and performed qRT-PCR. The second part I 
used to monitor the abundance of p53, Mdm2 and Fam83F by Western Blotting. 
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Although over-expression of Fam83F increased the abundance of p53 at the protein 
level, it did not increase the amount of p53 RNA (Figure 3.4). 
Although different degradation routes have been described for p53 (Tsvetkov et al., 
2010; Chao, 2015), the majority of p53 molecules are degraded by 26S proteasomes 
(Love et al., 2013). Since Fam83F increased p53 abundance by reducing its protein 
degradation, I wondered whether it is the proteasomal degradation pathway that is 
inhibited by Fam83F. To address this question, I over-expressed Fam83F in H1299 
cells together with p53 and Mdm2. Twenty-four hours after transfection, I treated a 
part of the cells with MG132, a peptide aldehyde that blocks the proteolytic activity 
of the 26S proteasome (Myung et al., 2001). For control, I treated the cells with 
DMSO, the solvent of MG132. 
 
 
 
 
Figure 3.5: Fam83F increases p53 abundance only in the presence of functional proteasomes. 
H1299 cells were transfected with plasmids encoding p53 together with plasmids encoding Fam83F 
or Mdm2 or both. 24 h after transfection, MG132 (10 μM f.c.) or DMSO, for control, were added. 16 
h after addition of MG132, cells were harvested and the abundance of p53, Mdm2 and Fam83F were 
determined by Western Blotting. Abundance of PCNA was determined for loading control.  
As shown in figure 3.5, the abundance of p53 was not affected by Fam83F when the 
cells were treated with MG132. In contrast, when the cells were only treated with the 
solvent, the influence of Fam83F on p53 abundance could be clearly observed 
(Figure 3.5). This result strongly suggests that Fam83F blocks the degradation of p53 
in 26S proteasomes. 
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3.2 Fam83F associates with p53  
Since Fam83F induces p53 abundance and since p53 levels are tightly controlled by 
Mdm2 (Haupt et al., 1997; Kubbutat et al., 1997), I wondered whether Fam83F 
might associate with p53 or Mdm2. Therefore, I transfected H1299 cells with a 
plasmid encoding Flag-tagged Fam83F and with a plasmid encoding p53. To see 
whether Fam83F associates with Mdm2  or eventually even requires the presence of 
both, p53 and Mdm2 at the same time for binding, I also transfected a plasmid 
encoding Mdm2 or vector DNA. I immuneprecipitated Fam83F and monitored 
associated p53 and Mdm2 abundance by Western Blotting. 
 
 
 
 
 
 
 
 
Figure 3.6: Fam83F interacts with p53. H1299 cells were transfected with plasmids encoding Flag-
tagged Fam83F and p53 together with a plasmid encoding Mdm2 or with vector DNA. 24 h after 
transfection, cells were lysed, Flag-tagged Fam83F was immune-precipitated and the associated p53 
and Mdm2 were monitored by Western Blotting. Precipitation with IgG was performed for control. 
An aliquot of the lysed cells was used to monitor the abundance of p53, Mdm2 and Flag-tagged 
Fam83F (Input). Hybridization with an antibody targeted against PCNA was performed for loading 
control. 
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As shown in figure 3.6, p53 associated with Fam83F, this interaction was further 
enhanced when Mdm2 was present (Figure 3.6). In contrast, Mdm2 did not co- 
precipitate with Fam83F (Figure 3.6).  
After having determined the association between p53 and Fam83F after 
overexpression, I wondered whether the two proteins might also interact with each 
other under physiologic conditions. For testing this, I immuneprecipitated Fam83F 
from RKO cells. As p53 is usually present in limited amounts in the cells, I treated 
the cells with hydroxyurea (HU) in order to increase p53 abundance. After immune-
precipitation, I monitored the associated p53 by Western Blotting. 
As shown in figure 3.7, p53 associated with Fam83F also when the proteins are not 
overexpressed, which confirms the previous result (Figure 3.7, Figure 3.6). 
 
 
 
 
 
Figure 3.7: Fam83F interacts with p53 in RKO cells. RKO cells were treated with 1.5 mM 
hydroxyurea (HU). 12 h after HU addition, cells were lysed and Fam83F was immune-precipitated. 
The associated p53 was monitored by Western Blotting. Precipitation with IgG was performed for 
control. An aliquot of the lysed cells was used to monitor the abundance of p53 and Fam83F (Input). 
Hybridization with an antibody targeted against PCNA was performed for loading control. 
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Since I found that Fam83F associates with p53, I wondered whether this interaction 
is direct or whether it may require additional proteins. 
To test this, I performed a GST-pulldown assay. I expressed His-tagged p53 and 
GST-tagged Fam83F in bacteria, purified these proteins and mixed them in a test 
tube. I then precipitated Fam83F using glutathione-sepharose and monitored the 
associated p53 by Western Blotting. 
 
 
 
 
 
Figure 3.8: Fam83F interacts directly with p53. His-tagged p53 was mixed with GST-tagged 
Fam83F. An aliquot of the mix was taken to monitor abundance of the two proteins (Input). From the 
remaining mixture, GST-Fam83F was precipitated by coupling to glutathione sepharose and the 
associated p53 was monitored by Western blotting. 
As shown in figure 3.8, His-tagged p53 co-precipitated with the GST-tagged 
Fam83F indicating that both proteins interact directly with each other (Figure 3.8). 
p53 and Mdm2 interact strongly with each other and this strong interaction is 
required for the degradation of p53 in 26S proteasomes (Haupt et al., 1997; Kubbutat 
et al., 1997). Fam83F furthermore bound p53 directly (Figure 3.8). Since Fam83F 
increases p53 abundance by preventing its degradation in 26S proteasomes, I 
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wondered whether Fam83F might interfere with the interaction of p53 with Mdm2. 
To address this, I transfected H1299 cells with plasmids encoding p53 and Mdm2. In 
addition, I transfected a plasmid encoding Fam83F or vector DNA, for control. 24 h 
after transfection, I immune-precipitated Mdm2 and monitored associated p53 (and 
Fam83F) by Western Blotting. Precipitation with IgG was performed for control. 
As shown in figure 3.9, Fam83F did not reduce the interaction between p53 and 
Mdm2. In fact, the interaction of p53 and Mdm2 was even enhanced in the presence 
of Fam83F, probably because of the higher amounts of p53 (Figure 3.9). This 
experiment furthermore confirms the previous result that Fam83F does not bind to 
Mdm2 (Figure 3.6). 
 
 
 
 
 
Figure 3.9: Fam83F does not interfere with the interaction of p53 and Mdm2. H1299 cells were 
transfected with plasmids encoding p53, Mdm2 and Fam83F as indicated. 24h after transfection, cells 
were harvested. An aliquot of the lysate was used to monitor the expression of p53 and Fam83F by 
Western blotting (Input). From the remaining cells, Mdm2 was immune-precipitated and associated 
p53 and Fam83F were detected by Western Blotting. Precipitation with IgG was performed for 
control. 
After having found that Fam83F and p53 co-precipitate, I determined the domains of 
the two proteins that interact. Therefore, I transfected H1299 cells with a plasmid 
expressing Flag-tagged Fam83F together with plasmids expressing V5-tagged full 
length p53, the p53 deletion mutant ∆1, comprising amino acid one to three hundred 
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or the deletion mutant ∆2, comprising amino acid one to one hundred-fifty and 
monitored associated p53 by Western Blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Fam83F associates with the C-terminus of p53. (A) Cartoon of the employed 
constructs of p53 and their interaction with Fam83F. (B) H1299 cells were transfected with plasmids 
encoding Flag-tagged Fam83F and the indicated V5-tagged full length (wt) or mutant forms of p53 
(∆1: 1-300 aa; ∆2: 1-150 aa). 24 h after transfection, cells were lysed, Flag-tagged Fam83F was 
immune-precipitated and the associated p53 was monitored by Western Blotting. Precipitation with 
IgG was performed for control. An aliquot of the lysed cells was used to monitor abundance of p53 
and Flag-Fam83F by Western Blotting (Input). Hybridization with an antibody targeted against 
PCNA was performed for loading control. 
A 
B 
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As shown in figure 3.10, only the full length p53 protein but not the deletion mutants 
interacted with Fam83F. This result indicates that the interaction with Fam83F 
involves the last 100 amino acids of p53. 
After having determined the domain of p53 which is involved in the interaction with 
Fam83F, I mapped the area on Fam83F that interacts with p53. Therefore, I 
transfected H1299 cells with a plasmid expressing p53 together with a plasmid 
expressing Flag-tagged full length Fam83F or the Flag-tagged deletion mutant ∆1, 
comprising amino acid one to three hundred and ninety-seven or the Flag-tagged 
deletion mutant ∆2, comprising amino acid one to two hundred and eighty-three. I 
immuneprecipitated Flag-tagged Fam83F and monitored the associated p53 by 
Western Blotting.  
As shown in figure 3.11, p53 associated with both deletion mutants of Fam83F as 
well as with wild type Fam83F, indicating that the interaction with p53 occurs via 
the N-terminal domain of Fam83F (Figure 3.11). 
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Figure 3.11: The N-terminus of Fam83F associates with p53. (A) Cartoon of the employed 
constructs of Fam83F and their interaction with p53. (B) H1299 cells were transfected with plasmids 
encoding the indicated full length (wt) or mutated forms of Flag-tagged Fam83F (∆1: 1-397 aa; ∆2; 1-
283 aa) together with a plasmid encoding p53. 24 h after transfection, cells were lysed, Flag- tagged 
wild type Fam83F or the Fam83F deletion mutants were immune-precipitated and the associated p53 
was monitored by Western Blotting. Precipitation with IgG was performed for control. An aliquot of 
the lysed cells was used to monitor abundance of p53 and Flag-Fam83F (Input). Hybridization with 
an antibody targeted against PCNA was performed for loading control. 
Since the N-terminus of Fam83F was sufficient for the interaction of Fam83F with 
p53, I wondered whether this domain might also be sufficient for regulating p53 
abundance. To address this, I transfected H1299 cells with plasmids expressing p53 
and Mdm2 together with a plasmid that either expressed full length Flag-tagged 
B 
A 
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Fam83F or Flag-tagged deletion mutants of Fam83F. I then monitored the 
abundance of p53, Mdm2 and Fam83F by Western Blotting. 
 
 
 
 
 
 
 
Figure 3.12: The N-terminus of Fam83F is necessary for inducing p53 abundance. H1299 cells 
were transfected with plasmids encoding p53, Mdm2 and the indicated full length (wt) and partially 
deleted forms of Fam83F (∆1: 1-397aa and ∆2: 1-283aa). 24 h after transfection, cells were lysed, and 
abundance of p53, MDM2 and Fam83F were determined by Western Blotting. Abundance of PCNA 
was determined for loading control. 
As shown in figure 3.12, the first 397 amino acids of Fam83F are sufficient for 
stabilizing p53. Most surprisingly, when further 114 amino acids were removed from 
the C-terminus (∆2; 1-283aa), induction of p53 was even stronger (Figure 3.12). 
Overall, these data strongly imply that the domain that is responsible for the 
induction of p53 resides in the N-terminal half of the Fam83F protein, the area that 
also interacts with p53 (Figure 3.11). 
3.3 Fam83F reduces p53 and Mdm2 ubiquitination 
p53 is a protein that shuttles between the nucleus and the cytoplasm (Roth et al., 
1998; Stommel et al., 1999). Since it was reported that nucleo-cytoplasmic shuttling 
of the p53 protein is essential for Mdm2-mediated degradation of the p53 protein 
(Roth et al., 1998), I thought to test whether Fam83F might eventually stabilize p53 
by sequestering the protein in the nucleus. 
Results  
74 
 
To address this question, I transfected H1299 cells with plasmids expressing Mdm2 
and p53 together with a plasmid that expresses Fam83F or with vector DNA. 
Twenty-four hours after transfection, I fractionated the cells into nuclear and 
cytoplasmic lysate and monitored the abundance of p53 and Fam83F by Western 
Blotting. To confirm the fractionation, I used GAPDH (glutaraldehyde phosphatdyl 
dehydrogenase) as a cytoplasmic marker and Histone H3 as a nuclear marker. 
In consistency with published data (Rotter et al., 1983), I found the majority of p53 
in the nucleus and only a minority in the cytoplasm (Figure 3.13). Overexpression of 
Fam83F did not change this pattern, indicating that Fam83F has no influence on the 
subcellular localization of p53. Surprisingly, in the presence of Fam83F and absence 
of Mdm2, I found more p53 protein in the cytoplasm (Figure 3.13). Of not, in 
consistency with data provided by genecards (www.genecards.org), Fam83F was 
present both in the cytoplasm and nucleus and thus in the same compartments as p53 
(Figure 3.13), which is also a prerequisite for the observed interaction of Fam83F 
and p53 (Figure 3.6). Hybridization of the Western Blots with antibodies targeted 
against GAPDH and Histone H3 show that the fractionation into the nuclear and 
cytoplasmic compartment was successful. 
 
 
 
 
Figure 3.13: Fam83F does not affect the sub-cellular distribution of p53. H1299 cells were 
transfected with plasmids encoding p53, Mdm2 and Fam83F as indicated. Cells were fractionated into 
cytoplasmic and nuclear lysates and abundance of p53 and Fam83F was determined by Western 
Blotting. Hybridization with antibodies targeted against GAPDH and Histone-H3 were performed for 
control (C: cytoplasmic fraction; N: nuclear fraction). 
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For confirming the result of the cell fractionation, I performed immune- fluorescence 
staining. Therefore, I cultured H1299 cells on gelatine-coated glass slices. Then, I 
transfected the cells with plasmids encoding p53 and Mdm2  together with a plasmid 
encoding Fam83F or with empty vector. Forty-eight hours after transfection, I fixed 
the cells and incubated them with antibodies targeted against p53 and Fam83F. To 
visualize the nuclei, I incubated the cells with Draq5, a fluorescent dye that binds to 
DNA. 
 
 
 
 
 
 
 
 
 
Figure 3.14: Fam83F and p53 are present in the same subcellular compartment. H1299 cells 
were cultured on gelatine-coated glass slides and transfected with plasmids encoding p53 and Mdm2 
together with a plasmid encoding Fam83F or with vector DNA. 48 h after transfection, cells were 
fixed with ice cold acetone-methanol and incubated with the anti-p53 antibody DO-1 (green) and anti-
Fam83F (red). After washing, cells were incubated with Alexa-fluor 448- and Alexa-fluor 546-
coupled anti-mouse and anti-rabbit antibodies together with Draq5 (blue). Thereafter, the slides were 
washed, mounted onto microscope slides and analysed with a Leica LSM microscope. 
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In agreement with the fractionation, the immunofluorescence staining showed that 
that p53 is predominantly located in the nucleus and largely excluded from the 
cytoplasm (Figure 3.14). The overexpression of Mdm2 resulted in a decrease in the 
intensity of the p53 signal. Fam83F was present in both, the cytoplasm and the 
nucleus. The overexpression of Fam83F did not alter the localization of p53 but 
resulted in an increase in the signal for p53 (Figure 3.14) which is consistent with the 
data obtained by Western Blotting (Figure 3.1).  
Degradation of p53 in 26S proteasomes requires prior ubiquitination (Fang et al., 
2000; Love et al., 2013). Since the N-terminus of Fam83F interacts with the C- 
terminus of p53, which holds the main ubiquitination sites of p53 (Rodriguez et al., 
2000; Lohrum et al., 2001), I wondered whether Fam83F might stabilize p53 by 
inhibiting its ubiquitination. To investigate this, I transfected H1299 cells with 
plasmids encoding p53, Mdm2 and Fam83F together with a plasmid encoding His- 
tagged ubiquitin. Twenty-four hours after transfection, I treated the cells with 
MG132  to stabilize  the  p53  protein  also  in  the  absence  of  Fam83F.  This  way,   
 
 
 
 
Figure 3.15: Ubiquitination of p53 is reduced by overexpressed Fam83F. H1299 cells were co-
transfected with plasmids encoding p53, His-tagged ubiquitin, Mdm2 and Fam83F in the indicated 
combinations. 24 h after transfection, cells were treated with 10 μM MG132 for 8 hours. Then cells 
were harvested. An aliquot of the cells was lysed in NP40 buffer and expression of p53, Mdm2 and 
Fam83F was determined by Western Blotting (Input). The remaining cells were lysed in guanidinium 
lysis buffer and ubiquitinated proteins were collected by adsorption to Ni
2+
 agarose. Ubiquitinated 
protein were eluted and separated by SDS-PAGE. Abundance of p53 was detected by Western 
Blotting. 
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it was possible to get similar amounts of the p53 protein both in the absence and in 
the presence of Fam83F that made it possible to compare the level of ubiquitination. 
Eight hours after addition of MG132, I harvested the cells and purified the 
ubiquitinated proteins by adsorption to Ni
2+
-agarose. I separated the ubiquitinated 
proteins by SDS-PAGE and monitored the amount of ubiquitinated p53 by Western 
Blotting. As shown in figure 3.15, overexpression of Fam83F reduced p53 
ubiquitination.  
Mdm2 is the main master regulator for p53 (Momand et al., 2000) and auto- 
ubiquitination of Mdm2 has been reported to promote p53 ubiquitination 
(Ranaweera and Yang, 2013). This raised the question whether Fam83F might 
reduce p53 ubiquitination because it interferes with Mdm2 auto-ubiquitination. To 
address this question, I transfected H1299 cells with plasmids encoding Mdm2 and 
Fam83F together  with  a  plasmid  encoding  His-tagged  ubiquitin. Twenty-four  
hours  after  
 
 
 
 
 
 
Figure 3.16: Ubiquitination of Mdm2 is reduced in the presence of Fam83F. H1299 cells were 
transfected with plasmids encoding His-tagged ubiquitin, Mdm2 and Fam83F. 24 h after transfection, 
cells were treated with 10 μM MG132 for 8 hours. Then the cells were harvested. An aliquot of the 
cells was lysed in NP40 buffer and expression of Mdm2 and Fam83F was determined by Western 
Blotting (Input). The remaining cells were lysed in guanidinium lysis buffer and ubiquitinated 
proteins were collected by adsorption to Ni
2+
-agarose. Ubiquitinated proteins were eluted and 
separated by SDS-PAGE. Abundance of Mdm2 was determined by Western Blotting. 
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transfection, I treated the cells with MG132 for eight hours. I harvested the cells, 
purified the ubiquitinated proteins by adsorption to Ni
2+
-agarose, separated the 
ubiquitinated proteins by SDS-PAGE and monitored the amount of ubiquitinated 
Mdm2 by Western Blotting. 
As shown in figure 3.16, similar to ubiquitination of p53, ubiquitination of Mdm2 
was strongly reduced after overexpression of Fam83F (Figure 3.16). 
3.4 Fam83F enhances the transcriptional activity of p53 
To investigate whether the increase in p53 abundance by Fam83F is also reflected by 
an increase in p53 activity, I performed a reporter assay. For this, I transfected 
MCF7 cells, which express wild type p53, with a plasmid encoding Fam83F together  
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Fam83F increases p53 activity. MCF7 cells were transfected with the p53- dependent 
reporter PG13 and with a plasmid encoding renilla luciferase, for transfection control, together with a 
plasmid encoding Fam83F or with vector DNA. 48 h after transfection, cells were lysed and firefly- 
and renilla–luciferase activity was determined. Relative firefly activity was calculated by 
normalization with the readings for renilla luciferase. The value of cells that had been transfected only 
with plasmids encoding the reporter was set to 1. The graph shows mean values and standard 
deviations of three independent experiments. The p-value was calculated by the two-tailed T test. 
*p<0.05. 
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with a plasmid encoding the p53-responsive reporter PG13 that possesses 13 repeats 
of the consensus p53-binding site fused to the gene for the firefly luciferase (El-
Deiry et al., 1993) and a plasmid encoding the renilla luciferase for internal control. 
Forty-eight hours after transfection, I measured the firefly and renilla luciferase 
activity and calculated the relative activity of p53. 
As shown in figure 3.17, there was a significant increase in p53 activity after 
overexpression of Fam83F, indicating that the increase in p53 abundance caused by 
Fam83F translates into more active p53. 
To further investigate the influence of Fam83F on p53 activity, I downregulated  
Fam83F in RKO cells by infection with a lentivirus containing a shRNA that was 
directed against Fam83F. After selection of Fam83F knockdown clones, I monitored 
the expression of Fam83F by Western blotting. 
 
 
 
 
 
 
Figure 3.18: Knockdown of Fam83F. RKO cells have been infected with lentiviruses carrying a 
shRNA directed against Fam83F or a control shRNA and the infected cells have been selected with 
0.5 μg/ml puromycin. Afterwards, the cells were analysed for the abundance of Fam83F, p53, p21 
and Bax, and for PCNA for loading control, by Western Blotting. 
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As shown in figure 3.18, the expression of fam83F was clearly reduced after 
infection with lentiviruses carrying a shRNA targeted against Fam83F. Knockdown 
of Fam83F furthermore reduced the steady-state level of p53 in RKO cells (Figure 
3.18). Since p21 and bax are target genes of p53 (El-Deiry et al., 1994; Miyashita et 
al., 1994), I also tested the levels of p21 and Bax. As shown in figure 3.18, p21 
levels were strongly reduced after downregulation of Fam83F while bax levels were 
no affected (Figure 3.18). 
One of the major activities of p53 is arresting the cell cycle (Agarwal et al., 1995; 
Shaw, 1996). Thus, if Fam83F indeed controls the activity of p53 then it should 
influence cell proliferation. In order to test this prediction, I monitored the 
proliferation of the RKO cells with downregulated Fam83F. Therefore, I plated a 
defined number of cells into the wells of a 24-well plate and counted the cells every 
day. 
 
 
 
 
 
Figure 3.19: Knockdown of Fam83F increases cell proliferation. RKO cells with downregulated 
Fam83F or the corresponding control cells with normal levels of Fam83F were plated at a density of 
10
4
 cells per well into a 24 well plate and counted every day. The graph shows mean values and 
standard deviations of three independent experiments. 
As shown in figure 3.19, knocking-down Fam83F enhanced the proliferation of 
RKO cells (Figure 3.19). 
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To confirm the result of the proliferation assay with downregulated Fam83F, I 
performed a clonogenic assay with overexpressed Fam83F. Therefore, I  transfected 
H1299 cells with plasmids encoding p53 and Mdm2 together with a plasmid 
encoding Fam83F or with vector DNA. For control I also transfected cells just with 
vector DNA. Twenty-four hours after transfection, I treated the cells with G418 to 
select for the transfected cells. Within the next two weeks, I allowed the transfected 
cells to form colonies. To visualize the colonies, I fixed them with methanol and 
stained them with crystal violet. I then analysed the result with the Image-J program. 
 
 
 
 
 
 
 
 
Figure 3.20: Overexpression of Fam83F inhibits cell proliferation. (A) H1299 cells were 
transfected with plasmids encoding Mdm2 and p53 together with a plasmid encoding Fam83F or with 
vector DNA. 24 h after transfection, the cells were treated with G418 (500 mg/ml) for 2 weeks. The 
colonies were visualized by staining with crystal violet and counted with the Image-J program. (B) 
The graphs shows mean values and standard deviations of the colony numbers of three independent 
experiments. ** P ≤ 0.01. 
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Consistent with earlier findings (Casey et al., 1991; Isaacs et al., 1991), 
overexpression of p53 reduced the number and size of the colonies (Figure 3.20). 
Importantly, overexpression of Fam83F resulted in a further reduction of the number 
of colonies (Figure 3.20). 
3.5 Fam83F is induced in response to DNA damage 
p53 is strongly induced and activated in response to DNA damage (Lakin and 
Jackson, 1999; Hirao et al., 2000). Since Fam83F significantly increases p53 
abundance and activity, I wondered whether Fam83F might also be induced by DNA 
damage and thus contribute to the activation of p53 in response to DNA damage. To 
address this, I incubated human fibroblasts with 50 μM etoposide. Etoposide forms a 
ternary complex with DNA and inhibits topoisomerase II (Walles et al., 1996). This 
inhibition of topoisomerase II leads to the generation of DNA double strand breaks. 
After addition of etoposide to the human fibroblasts, I harvested the cells after 
increasing time points and monitored the abundance of Fam83F, p53 and Mdm2 by 
Western blotting. 
 
 
 
 
Figure 3.21: Fam83F is induced in response to etoposide. Primary human fibroblasts (GM38) were 
treated with 50 μM etoposide for the indicated time. The cells were harvested and the abundance of 
Fam83F, p53 and Mdm2 was determined by Western Blotting. Hybridization with an antibody 
targeted against PCNA was performed for loading control. 
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As shown in figure 3.21, Fam83F levels were induced by etoposide. The increase in 
Fam83F protein levels was already visible at one hour after addition of etoposide. 
With increasing time Fam83F levels were further increased (Figure 3.21). Induction 
of p53 could also be observed already at one hour after etoposide addition and p53 
also accumulated further with time. In fact, p53 and Fam83F showed similar kinetics 
of induction. Mdm2, a transcriptional target of p53, was induced later and 
accumulated from four hours after etoposide addition onwards until the end of the 
experiment (Figure 3.21). 
To confirm and extent the result with etoposide, I treated the primary fibroblasts also 
with DNA damaging agents that induce other kinds of lesions. To this end, I used 
methyl-methansulfonate (MMS; Lundin et al., 2005), a compound that alkylates the 
bases of the DNA, ultraviolet light (UVC; Goto et al., 2015) that induces thymidine 
dimers and 4-6-photoproducts in the DNA, and hydroxyurea that oxidizes and 
depurinates the DNA (Sakano et al., 2001). For MMS and etoposide treatment, I 
added the drug and harvested the cells at increasing times after drug addition. For 
UVC-treatment, I removed the medium from the cells, washed the cells with PBS, 
exposed them to UVC light, added the original medium back to the cells and 
harvested the cells after increasing times. For the treatment with hydroxyurea, I 
treated the RKO cells with hydroxyurea for seventeen hours. Then I removed the 
medium and washed the cells excessively with PBS and harvested the cells after 
increasing times. 
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Figure 3.22: Fam83F is induced in response to DNA damage. (A) Primary human fibroblasts 
(GM38) cells were exposed to UVC light (30 J/m
2
), Etoposide (50 mM) and methyl methanesulfonate 
(MMS; 5 mM). Cells were harvested at the indicated times and lysed. Abundance of Fam83F was 
monitored by Western Blotting. PCNA was used for loading control. (B) RKO cells were treated with 
1.5 mM hydroxyurea (HU) for 17 hours. Then the HU was removed and cells were washed with PBS 
and incubated with fresh medium. The cells were harvested at the indicated time points after HU 
release (ctrl: untreated cells). Abundance of Fam83F and p53 was monitored by Western Blotting. 
PCNA was used for loading control. 
As shown in figure 3.22, Fam83F was induced in response to all adverse agents 
(Figure 3.22). The induction of Fam83F again mirrored the induction of p53 (Figure 
3.21; Figure 3.22-B) although the induction of p53 appeared to be stronger which 
may be due to the higher amount of p53 available in the cells.  
p53 is activated in response to DNA damage and induces p21, an inhibitor of cyclin-
dependent kinases and cell cycle arrest (Ding et al., 2003). Since Fam83F induces 
p53 activity and is also upregulated in response to DNA damage, I wondered 
whether Fam83F might be required for the full activation of p53 in response to DNA 
damage. To answer this question, I employed the RKO cells that had been infected 
with lentiviruses to downregulate Fam83F (Figure 3.18). I irradiated these cells with 
UVC-light or treated them with etoposide or hydroxyurea and monitored the 
expression of p53 and p21. 
A 
B 
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Figure 3.23: Knockdown of Fam83F reduced p21 expression in response to DNA damage. RKO 
cells that had been infected with a control shRNA and RKO cells that had been infected with a 
shRNA targeted against Fam83F were treated with hydroxyurea (HU; 1.5 mM) or etoposide (Eto; 20 
mM), or irradiated with UVC (UV, 30 J/m
2
). 12 hours after the treatment, cells were harvested. 
Abundance of p21 and p53 was monitored by Western Blotting. PCNA was used for loading control. 
As shown in figure 3.23, downregulation of Fam83F reduced the expression of p21 
after treatment with etoposide or hydroxyurea. In contrast to the treatment of the 
cells with etoposide or hydroxyurea, I could not detect induction of p21 after 
irradiation of the cells with UV-light. Surprisingly, I could not detect a decrease in 
the expression of p53 after DNA damage when Fam83F was downregulated (Figure 
3.23). 
3.6 Fam83F interacts with mutant p53 
In a recent report, Fam83F was shown to be a target of microRNAs and 
downregulation of Fam83F by microRNAs resulted in tumour-inhibition (Mao et al., 
2016; Yang et al., 2017). These findings are in contrast to my own results where 
Fam83F showed growth suppressive activities. One resolution to this discrepancy 
could be provided by the mutational status of p53. It is known since several years 
that p53 is frequently mutated in human cancer and mutations in p53 are a hallmark 
of oesophageal squamous cell carcinoma (Liang et al., 1995; Ireland et al., 2000). 
Most importantly, mutant p53 is not just an inactive protein. Instead, mutant p53 
frequently gains oncogenic activities (Freed-Pastor and Prives, 2012). If Fam83F 
would also control mutant p53 then this activity could explain the above mentioned 
discrepancy. To investigate this, I first determined whether Fam83F and mutant p53 
Results  
86 
 
interact. Therefore, I transfected H1299 cells with a plasmid encoding wild-type p53 
or a gain of function mutant of p53 (R273H or R175H) together with a plasmid 
encoding Flag-tagged Fam83F or with vector DNA. Twenty-four hours after 
transfection, cells were lysed, Flag-tagged Fam83F was immune-precipitated and the 
associated p53 was monitored by Western Blotting.  
 
 
 
 
 
Figure 3.24: Fam83F interacts with mutant p53. H1299 cells were transfected with plasmids 
encoding wild-type (wt) p53 or the p53 mutants R175H or R273H together with a plasmid encoding 
Flag-tagged Fam83F or with vector DNA. 24 hours after transfection, cells were lysed, Flag-tagged 
Fam83F was immune-precipitated and the associated p53 was monitored by Western Blotting. An 
aliquot of the lysed cells was used to monitor abundance of p53 and Flag-Fam83F (Input). 
Hybridization with an antibody targeted against PCNA was performed for loading control. 
As shown in figure 3.24, mutant p53 associated with Fam83F to the same extent as 
wild type p53 (Figure 3.24). 
I then wondered whether Fam83F might influence the abundance of mutant p53. To 
investigate this I transfected H1299 cells with plasmids encoding wild-type or 
mutant p53 (R175H or R273H) together with plasmids encoding Mdm2 and 
Fam83F, or with vector for control. Twenty-four hours after transfection, I 
monitored p53 levels by Western Blotting. As shown in figure 3.25, overexpression 
of Fam83F did not affect the abundance of the p53 mutants R273H and R175H. 
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Figure 3.25: Fam83F does not regulate the abundance of mutant p53. (A) H1299 cells were 
transfected with plasmids encoding wild-type (wt) p53 or the p53 mutant R273H, Mdm2 and Fam83F 
in the indicated combinations. (B) H1299 cells were transfected with plasmids encoding wild type 
(wt) p53 or the p53 mutant p53 R175H, Mdm2 and Fam83F in the indicated combinations. 
Abundance of p53, Mdm2 and Fam83F was monitored by Western Blotting. Hybridization with an 
antibody targeted against PCNA was performed for loading control. 
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4. Discussion 
Although p53 was initially regarded as an oncogene, it is known for several decades 
that p53 is frequently mutated in cancer (Takahashi et al., 1989). Moreover, cells 
lacking p53 have been shown to be cancer prone (Donehower et al., 1992). p53 is 
activated in response to various stresses and induces expression of different genes 
whose protein products mediate apoptosis, cell cycle arrest, senescence, autophagy, 
inhibition of angiogenesis and regulation of energy metabolism (Vogelstein et al., 
2000; Beckerman and Prives, 2010). Under normal conditions, p53 is maintained at 
low levels, primarily by the oncoprotein Mdm2 that directly inhibits p53’s 
transcriptional activity and that, as a RING-finger-containing ubiquitin ligase, targets 
p53 for proteasomal degradation (Momand et al., 1992; Chen et al., 1995; Haupt et 
al., 1997; Kubbutat et al., 1997). Mdm2 also mediates p53 nuclear export (Roth et 
al., 1998). 
Although p53 is one of the most extensively studied proteins, much still remains to 
be elucidated; particularly as the p53 network is complex and many regulators that 
are involved in the p53 network are still unknown. In this study, I investigated the 
regulation of p53 by Fam83F, a novel regulator of p53 that was recently identified in 
our lab (Zhang et al., 2015). 
4.1 Fam83F increases the abundance of p53 
Fam83F is one of the genes that had been identified by screening a cDNA library 
from medaka (Oryzias latipes) for proteins that alter the abundance of p53 and or 
Mdm2 (Zhang et al., 2015). In this screen, Fam83F was found to increase p53 
abundance with no effect on Mdm2 levels (Zhang et al., 2015). I confirmed this 
result using the human fam83F gene. The increase in Fam83F levels correlated 
strongly with the amount of transfected fam83F. However, the increase in p53 
abundance was only seen when Mdm2 was also overexpressed. This result indicates 
that Fam83F regulates p53 abundance in an Mdm2-dependent manner. In contrast to 
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the protein, I did not find any evidence for a regulation of p53 RNA by Fam83F. 
Overexpression of fam83F even decreased the amount of p53 RNA. This result 
strongly implies that Fam83F regulates p53 at the protein level. The increase in p53 
abundance was due to a strong reduction in its degradation. When I treated the cells 
with cycloheximide, I observed that overexpression of fam83F greatly extended the 
half-life of p53. 
p53 abundance is primarily controlled by its protein stability and Mdm2-mediated 
ubiquitination and degradation is the main regulator for this process. I have observed 
that Fam83F stabilizes p53 by reducing its degradation in 26S proteasomes. As 
ubiquitination of p53 is a strong requirement for this process (Varshavsky, 1997), I 
expected that Fam83F may interfere with p53 ubiquitination. Indeed, overexpression 
of fam83F strongly reduced p53 ubiquitination. In addition, Fam83F also reduced 
Mdm2 auto-ubiquitination. Since auto-ubiquitination of Mdm2 promotes p53 
polyubiquitination (Ranaweera and Yang, 2013), it is possible that Fam83F 
suppresses p53 ubiquitination by reducing Mdm2 auto-ubiquitination. 
The reduction in p53 and Mdm2 ubiquitination after overexpression of fam83F 
implies that it may directly interact with these proteins. Indeed, I could show that the 
N-terminus of Fam83F associates with the C-terminus of p53. The six C- terminal 
lysine residues of p53 are the predominant sites for Mdm2 mediated ubiquitination 
(Lohrum et al., 2001). Thus, an alternative possibility for the reduced ubiquitination 
of p53 is that binding of Fam83F to the C-terminus of p53 might mask the 
ubiquitination sites in the C-terminus of p53. Ubiquitination and degradation of p53 
requires a strong binding to Mdm2. Therefore, a further possibility how Fam83F 
could reduce p53 ubiquitination and degradation would be by interfering with the 
binding of p53 to Mdm2. I investigated this possibility, but in contrast to my 
expectations, Fam83F did not reduce the interaction of p53 with Mdm2. Mdm2 is a 
RING-domain containing E3 ubiquitin ligase that associates with an E2 ubiquitin-
conjugating enzyme to facilitate the transfer of the ubiquitin onto p53 (Fang et al., 
2000; Honda and Yasuda, 2000). Since Fam83F did not interact with Mdm2, but 
strongly reduced its ubiquitination, it is possible that Fam83F associates with the E2 
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enzyme and reduces the association of the E2 enzyme and Mdm2. This could explain 
why p53 and Mdm2 ubiquitination is reduced by Fam83F without interacting with 
Mdm2. A further possible explanation how Fam83F could stabilize p53 is related to 
the shuttling activity of p53 and Mdm2. p53 and Mdm2 shuttle back and forth 
between the nucleus and the cytoplasm (Liang and Clarke, 2001) and this shuttling 
activity is important for the degradation of p53 in the cytoplasm. Thus, Fam83F 
could eventually stabilize p53 by sequestering it in the nucleus. This would then 
protect p53 from its degradation in the cytoplasm. Therefore, I examined whether 
Fam83F sequesters p53 in the nucleus. However, cell fractionation showed that 
Fam83F has no influence on p53 localisation. 
4.2 Fam83F enhances p53’s transcriptional activity 
The p53 protein is a transcription factor that regulates the expression of a large 
number of target genes (Vogelstein et al., 2000). By this p53 can induce a number of 
different responses ranging from cell death, induction of cell cycle arrest and 
senescence to DNA repair (Vogelstein et al., 2000; Khoo et al., 2014). In order to 
investigate whether the increase in p53 abundance caused by Fam83F is also 
reflected by an increase in p53 activity, I did a reporter assay and I could show that 
overexpression of fam83F enhanced p53 activity strongly in MCF7 cells. One of the 
major activities of p53 is inducing cell cycle arrest to inhibit the proliferation of 
cancer cells (Vogelstein et al., 2000; Khoo et al., 2014). I could furthermore show 
that overexpression of fam83F enhanced p53 activity significantly in a colony 
forming assay. Vice versa, downregulation of endogenous Fam83F in RKO cells 
resulted in a decrease in p21 expression that was further validated in a proliferation 
assay where RKO cells showed enhanced cell proliferation after knocking-down 
Fam83F. 
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4.3 Fam83F and mutant p53  
Fam83F expression was shown to be regulated by miR-143 through decreasing its 
mRNA stability in cells from oesophageal carcinoma (ESCC; Mao et al., 2016). The 
role of Fam83F in the control of cell proliferation was investigated in human ESCC 
cell lines including the cell lines KYSE410 and ECA109 by performing a colony 
forming assay. The result of this assay showed that a miR-143-resistant mutant form 
of Fam83F attenuated the anti-proliferative effect of miR-143. p53 is mutated in 
about 50% of all human cancer (Bykov and Wiman, 2003). ESCCs have several 
specific molecular alterations and apart from tumour cell aneuploidy, p53 mutations 
are a hallmark of ESCCs (Reid et al., 2001; Wongsurawat et al., 2006; Souza, 2010). 
Since in this recent report of Fam83F regulation by miR-143 (Mao et al., 2016) there 
was no analysis of p53 mutations, it is possible that p53 was mutated in these cells. 
Surprisingly, co-immuneprecipitations showed an association between Fam83F and 
mutant p53 (R273H and R175H). This result opens a window for further research 
into the role of Fam83F in the regulation of mutant p53. The infulance of Fam83F on 
mutant p53 might explain the speculation that Fam83F has a dual funcation 
dependant on the status of p53 in the cell. I could show that Fam83F does not affect 
the abundance of mutant p53 (R273H and R175H) in the presence of Mdm2, 
possibly because mutant p53 is already a very stable protein. Fam83F is most likely 
unable to regulate the abundance of mutant p53, since Fam83F acts by stabilizing 
wild type p53 in Mdm2 dependant manner and tha mutant forms of p53 are already 
very stable proteins. This has been shown in previous reports that used the increased 
stability and thus high abundance of mutant p53 as a diagnostic indicator for stable 
p53 in human cancers by immunohistochemistry (IHC; Hall and Lane, 1994). Most 
tumour suppressor proteins are usually downregulated in various tumours. The p53 
protein is unique in this regard since high levels of missense mutations of p53 are 
present in various tumours. These levels of mutant p53 are clearly higher than wild-
type p53 in normal unstressed cells (Olivier et al., 2002). Such high levels of p53 
furthermore correlated with a particularly aggressive behaviour of the tumours 
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(Oshiro et al., 1998; Petitjean et al., 2007; Rivlin et al., 2011). In contrast to wild-
type p53, mutant p53 does not form a feedback-loop with Mdm2 as mutant p53 does 
not induce Mdm2 transcription (Midgley et al., 1997). A possible explanation that 
Fam83 does not stabilize mutant p53 is that mutant p53 escaped the Mdm2 
degradation pathway that is required by Fam83F to stabilize the wild type p53. 
4.4 Fam83F is induced in response to DNA damage 
DNA damage efficiently induces a p53 response, in part through the activation of 
ATM/ATR kinases that result in the phosphorylation of p53 and Mdm2. This 
phosphorylation can inhibit the interaction between these two proteins, allowing the 
stabilization of p53 (Banin et al., 1998; Khosravi et al., 1999; Sakaguchi et al., 
2000). In addition to the stabilization of p53, DNA damage-induced kinases also 
plays a role in the activation of p53 as a transcription factor, in part by promoting 
acetylation within the C-terminus of p53 (Lambert et al., 1998; Sakaguchi et al., 
1998; Ou et al., 2005). Since Fam83F induces p53 transcriptional activity through its 
interaction with the C-terminus of p53, I tested whether Fam83F also induces p53 
activity in response to DNA damage. Indeed, Fam83F was induced in response to 
DNA damage. The expression of p21 can be directly transactivated by wild-type 
p53. Knockdown of Fam83F resulted in a reduction of p21 levels when cells were 
treated with DNA damaging agents. This result suggests that p53 activity is reduced 
upon Fam83F knockdown in response to DNA damage. Although p21 expression 
was reduced after downregulation of Fam83F in RKO cells. I was not able to see a 
reduction in p53 abundance. This result indicates that p53 accumulates but is 
functionally impaired by the Fam83F knockdown. Accumulation of p53 and 
activation are not necessarily directly linked, as shown previously by Gottifred and 
co-workers. Most interestingly, they could show that despite higher levels of p53 
after ionising radiation compared to treatment with hydroxyurea, they were unable to 
detect an accumulation of p21 or Mdm2 (Gottifredi et al., 2000). 
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4.5 Conclusions 
With this work, I can add a new piece to the puzzle of p53 regulation. I could show 
that Fam83 induces the abundance of wild type p53 in a proteasome-dependent 
manner by reducing its ubiquitination. Fam83F interacts with the C-terminal domain 
of p53 that holds the main ubiquitination sites. This interaction via the C-terminus 
suggests that Fam83F may reduce ubiquitination of p53 by masking the lysine 
residues in the C-terminal domain of p53. The increase in p53 abundance was 
furthermore reflected by an increase in p53 activity. Fam83F was upregulated in 
response to DNA damage and knockdown of Fam83F reduced the expression of p21 
which resulted in increased proliferation. 
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5. Outlook 
Fam83F is a relatively uncharacterized protein. Until 2014, there were no 
publications about the role of Fam83F in the cell. Thus, it was a gene with unknown 
function. The first observation about Fam83F as a positive regulator of p53 was 
identified in our laboratory (Zhang et al., 2015). 
In 2016, it was published that Fam83F is regulated by miR-143 and that it is 
upregulated in oesophageal squamous cell carcinoma (ESCC; Mao et al., 2016). 
Introducing miR-143 into ESCC cells downregulated Fam83F and resulted in 
inhibition of cell proliferation. Other researchers also working on ESCC found that 
Fam83F is also regulated by miR-455-3p although they did not show that the 
regulation of cell proliferation by miR-455-3p is really due to the regulation of 
Fam83F (Yang et al., 2017). My research and these reports open a new window for 
research. Since p53 is frequently mutated in human cancer and p53 mutation is a 
hallmark in ESCCs, it is possible, that p53 was mutant in the ESCC cells that were 
investigated by Mao and colleagues. During my investigation of the molecular 
mechanism of p53 regulation by Fam83F, I found that Fam83F also interacts with 
mutant p53. This raises the possibility that Fam83F might eventually also activate 
mutant p53 and may act as a tumour suppressor or an oncogene, depending on the 
status of p53 in the cell. 
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